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In recent years the molecule programmed death-1 (PD-1) has attracted much 
attention for several reasons. First, it is a critical element in the negative regulation 
of cellular immune responses. Second, blockage of the interaction between 
PD-1 expressed on T cells and its ligand PD-L1 expressed on tumor cells has 
emerged as a promising approach in the treatment of several cancers. Third, PD-1 
is constitutively expressed by a subset of T cells, namely follicular helper T cells 
which play a key role in the differentiation of germinal center B cells into memory 
B cells or plasma cells. Fourth, expression of PD-1 has been used as important 
biomarker in the differentiation between different types of T-cell non-Hodgkin 
lymphoma. The main focus of the studies in this thesis was to determine whether 
expression of PD-1 might also be a useful marker in the diagnosis of different types 
of cutaneous lymphoma. 
In this introductory chapter we will fi rst describe general knowledge about the 
PD-1 molecule and the physiological role of PD-1 in cellular and humoral immunity. 
Next, expression of PD-1 in different types of nodal non-Hodgkin lymphoma and 
its diagnostic signifi cance will be presented. Finally, primary cutaneous T-cell 
lymphoma and outstanding issues will be introduced and PD-1 related important 
contributions will be explained. 
DISCOVERY AND DESCRIPTION OF THE PD-1 MOLECULE
PD-1 (CD279) was originally identifi ed in 1992 by Ishida et al. who were studying 
dependency of programmed cell death on de novo RNA and protein synthesis. In 
mouse cell lines that were induced to undergo apoptosis they discovered that the 
PD-1 gene was activated and involved in this type of cell death.1 Human full-length 
PD-1 was identifi ed two years later as a type I trans-membrane glycoprotein of 288 
amino acids (aa) and the PD-1 gene (named PDCD1) was mapped to chromosome 
2q37.3. Ref 2 The extracellular regions of human and mouse PD-1 are relatively highly 
conserved (approximately 65% homology).3 PD-1 is considered to belong to the 
immunoglobulin (Ig) superfamily, because the structure of the extracellular domain 
resembles an Ig variable region (IgV). PD-1 is a monomer molecule and structurally 
related to family members CD28 and CTLA-4, which are functional as homodimer 
molecules.4 The extracellular domain of PD-1 is connected to a transmembrane 
region and an intracellular tail (Figure 1), containing two phosphorylation sites called 
ITSM (immunoreceptor tyrosine–based switch motif) and ITIM (immunoreceptor 
tyrosine–based inhibitory motif). Splice variants of the human PD-1 gene have 
been reported.5 One splice variant that lacks the transmembrane region represents 
the soluble form of PD-1, which can functionally antagonize the interaction of cell 

















DISCOVERY AND DESCRIPTION OF THE PD-1 LIGANDS
PD-1 has two ligands named PD-L1 (CD274; B7-H1) and PD-L2 (CD273; B7-DC). 
Human PD-L1, which was discovered in 2000, is 290 aa in size and is encoded by 
the CD274 gene on chromosome 9. Ref 7 One year later PD-L2 was identifi ed as 
a glycoprotein consisting of 273 aa and being encoded by the PDCD1LG2 gene 
(Table 1).8 The CD274 and PDCD1LG2 genes are located next to each other and 
separated by only 42 kb of intervening genomic DNA. PD-L1 and PD-L2 share 40% 
aa identity. Both PD-1 ligands are type I transmembrane molecules and member 
of the Ig superfamily. Like PD-1, the extracellular part of PD-L1 and PD-L2 contains 
one IgV–like domain, but unlike PD-1, the extracellular part of PD-L1 and PD-L2 
also contains one additional Ig constant region (IgC)–like domain (Figure 1). The 
intracellular domains of PD-L1 and PD-L2 are relatively short, only about 30 aa, 
without clear signaling motifs, but it is suggested that these intracellular tails may 
have a functional roles.9 PD-L2 has a two- to six-fold higher affi nity for PD-1 than 
does PD-L1. Ref 10
Ligands PD-L1 and PD-L2 also have splice variants and soluble forms with PD-1 
binding capacity (Figure 1; Table 1), 11-13 but their role is unclear. Soluble PD-L1 is 
released by activated dendritic cells, but not by macrophages, monocytes or T 
cells.14 In addition, soluble PD-L1 is also produced by various tumor cells.14 
Figure 1. Structures of the PD-1 molecule and its ligands PD-L1 and PD-L2. PD-1 contains an 
extracellular Ig variable region (IgV)–like domain and an intracellular tail with two tyrosine-containing 
sites, called ITSM and ITIM, which are phosphorylated when PD-1 binds its ligand PD-L1 or PD-L2. The 
extracellular part of ligands PD-L1 and PD-L2 contains one IgV–like domain and one Ig constant region 
(IgC)–like domain and both have a relatively short intracellular domain without clear signaling motifs. 
In addition, PD-L2 (type II) contains only one IgV–like domain. The molecular structure of the soluble 

















Although it is typically thought that PD-L1 and PD-L2 interact with PD-1, it is 
important to note that there are other binding partners for these two ligands (Table 
1). PD-L1 has been shown to interact specifi cally with CD80 (B7-1).15 Keeping in mind 
that CD80 can also bind to CD28 and CTLA-4, it is diffi cult to comprehend how 
this complex receptor–ligand interactions is exactly balanced. Very recently, it is 
reported that PD-L2 can also bind to repulsive guidance molecule b (RGMb, also 
known as DRAGON),16 which was originally identifi ed in the nervous system as a 
co-receptor for bone morphogenetic proteins and is expressed by macrophages 
and other cells of the immune system.17
EXPRESSION OF PD-1 AND ITS LIGANDS PD-L1 AND PD-L2
In humans, PD-1 can be expressed on T cells, B cells, natural killer T cells, monocytes 
and myeloid CD11c+ dendritic cells (DC) after activation.9;18 PD-1 is not present 
on naïve T cells, but is induced on CD4+ and CD8+ T cells after T-cell receptor–
mediated activation and remains high in case of persistent stimulation with antigen 
(Table 2). In addition, PD-1 can also be induced on T cells by the so-called common 
gamma-chain cytokines interleukin 2 (IL-2), IL-7, IL-15 and IL-21, which are important 
for survival and expansion of T cells.19 PD-1 is highly expressed on non-functional 
so-called “exhausted” T cells,20 which are the result of persistent antigen exposure, 
caused by chronic viral infections or progressive tumors.21 Remarkably, follicular 
helper T (TFH) cells, which are key regulators of germinal center B cell differentiation 
into plasma cells and memory B cells, have a constitutive high expression of PD-1. Ref 
22 Regulatory T (Treg) cells, which suppress immune system activation and promote 
immunologic tolerance, also have a constitutive high PD-1 expression.23 Triggering 
of the B-cell receptor stimulate PD-1 expression on B cells.9;18 Freshly isolated NK 
cells from healthy donors do not express PD-1, but IL-2 can induce PD-1 expression 
on NK cells.24 Freshly isolated immature Langerhans cells from healthy donors 
express PD-1, but lose this expression after maturation.25
Table 1. General facts on human PD-1 and ligands PD-L1 and PD-L2
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PD-L1 expression is found on a broad range of immune cells (Table 2), including T 
cells and antigen-presenting cells, and is upregulated after activation.9 In particular 
type I and type II interferons can upregulate PD-L1 expression. PD-L1 can also 
be induced on a variety of non-immune cells, such as epithelial cells including 
keratinocytes and endothelial cells. Of note, tumor cells have been reported 
to express PD-L1 as well. Expression of PD-L2 has initially been reported to be 
restricted to activated professional antigen-presenting cells (Table 2), but recently 
it was shown that PD-L2 is expressed on activated human CD4+ and CD8+ T cells 
as well.26
SUPPRESSION OF T-CELL FUNCTION BY THE PD-1/PD-L AXIS
T cells become activated when their T-cell receptor (TCR) recognizes an antigenic 
peptide−MHC complex that is presented by antigen-presenting cells. TCR are 
associated with CD3, which actually mediate the activation signal via activation 
of a series of kinases, such as ZAP70, PI3K, PKC- and AKT (Figure 2). T cells 
concomitantly receive multiple additional antigen-independent signals via receptor/
ligand interactions, collectively called costimulation, which can deliver positive or 
negative signals.27 Positive costimulation is essential for naïve T cells to become 
fully activated and if there is no or not enough positive signaling, naïve T cells 
fail to develop into effector or memory T cells and become nonresponsive to 
subsequent antigen stimulation, a situation which is often indicated with the term 
Table 2. Expression of PD-1, PD-L1 and PD-L2 on human cells *
PD-1 PD-L1 PD-L2
Basal # Activated # Basal # Activated # Basal # Activated #
CD4+ T cells – +++ – + – +
CD8+ T cells – +++ – + – +
Exhausted T cells – +++ nd nd nd nd
CD4+ regulatory T cells ++ +++ + + – –
CD4+ follicular
helper T cells
++ +++ nd + – –
B cells – ++ nd ++ – – 
Monocytes – + + ++ – + 
DC – + + + – ++ 
Langerhans cells + – + ++ + ++
Keratinocytes – – – + – – 
* adapted from Keir et al. 9 and explained in detail in the text; nd: not determined

















anergy.28 Predominance of negative co-stimulation will induce the development 
of regulatory T cells, T-cell tolerance or apoptosis. Receptors of the CD28/CTLA-4 
family, including PD-1, have a key role in the outcome of T-cell responses, as these 
receptors provide potent costimulatory or inhibitory signals upon interaction with 
their corresponding ligands. 
Costimulation is highly complex, because some of these receptor and ligands 
are constitutively expressed while others appear on the cell surface after activation, 
and in addition, some of the receptors have dual specifi city or have similar 
specifi city with different affi nity (Figure 2). To provide a detailed description of 
the costimulatory and inhibitory signals is beyond the scope of this thesis, though 
an extensive overview can be obtained from references.27 Only the PD-1/PD-L 
signaling will be described here, as PD-1 is the primary molecule of interest in 
this thesis.
Figure 2. Inhibition of T-cell activation by PD-1. Antigen recognition by the T-cell receptor (TCR) 
provides an activation signal via CD3. Concomitant binding of CD28 to its ligand CD80 or CD86 
strongly promotes T-cell activation, while ligation of PD-L1 or PD-L2 to PD-1 causes recruitment of 
phosphatase SHP-2 that disrupts the TCR and CD28 signaling pathway. A more detailed description 

















Upon binding to its ligand, PD-1 becomes associated with TCR and CD28 
microclusters that are assembled in the so-called immunological synapse.29;30 In 
addition, phosphorylation of the two intracellular tyrosine-based domains ITSM 
and ITIM takes place, which leads to the recruitment of phosphatases SHP-2 and 
possibly SHP-1 as well.9 Mutagenesis studies have shown that recruitment of 
SHP-2 by ITSM plays the primary functional role of PD-1 inhibition.31 The binding 
of SHP-2 by ITSM results in dephosphorylation of several molecules of the TCR 
signaling pathway (Figure 2).32;33 Altogether, triggering of PD-1 on the T cell leads 
to inhibition of proliferation and cytokine production, such as IL-2 (which protects 
against apoptosis), IFN- and TNF-, and promotes T-cell apoptosis through 
inhibition of survival factor Bcl-xL.9
PD-1+ T FOLLICULAR HELPER CELLS AND B-CELL IMMUNITY
The differentiation of naïve B cells into memory B cells or antibody-secreting 
plasma cells in the germinal centers within the B-cell follicles is critically dependent 
on so-called T follicular helper (TFH) cells.34;35 In both humans and mice, TFH cells 
typically are CD4+ T cells with a high expression of chemokine receptor CXCR5 
(chemokine C-X-C motif receptor 5) and CXCL13 (chemokine C-X-C motif ligand 13) 
and further express ICOS (inducible T cell costimulator), BCL6 (transcription factor 
B-cell lymphoma 6) and the cytokine IL-21. Of note, TFH cells have a constitutively 
high expression of PD-1, which is assumed to be one of the key instructive signals 
to guide the differentiation of germinal center B cells into memory or plasma cells.36 
These markers together are valuable to defi ne TFH cells, but no single marker is 
suffi cient to detect TFH cells as each of them can be found in other T cell subsets. 
Although TFH are defi ned by follicular location, T cells fulfi lling the phenotypical 
criteria of TFH can also be detected outside the lymphoid organs, for example in 
the blood circulation. PD-1 is an important negative regulator of B-cell responses in 
the periphery. Binding of PD-1 to its ligand causes phosphorylation of the ITSM and 
ITIM domains of the B-cell receptor, causing recruitment of phosphatase SHP-2, 
leading to dephosphorylation of key molecules immediately downstream of the 
B-cell receptor, thereby suppressing the activation of the B cell.9 Blockade of PD-1 
on B cells enhances antigen-specifi c antibody responses.37
TUMORS AND THE PD-1/PD-L PATHWAY
In mouse models it has been demonstrated that PD-L1 expressing tumor cells are 
resistant to killing by CD8+ T cells via the engagement of PD-1 on the T cells by 

















inhibition of the T-cell mediated cytotoxicity, while blockade of this interaction with 
antibodies restored the anti-tumor response.38-40 These data highlight that tumors 
can use the PD-1/PD-L pathway as evasion mechanism to escape from the immune 
system. Indeed, many different tumor types have upregulated PD-L1 expression41 
and the majority of the tumor infi ltrating lymphocytes show PD-1 expression.42;43 
Therefore, the PD-1/PD-L pathway is generally considered to have a central role in 
the strategy of tumors to avoid eradication by the host defense system.
The exact mechanism why PD-L1 is expressed by tumor cells is currently 
unclear. Constitutive oncogene-driven expression of PD-L1 has been suggested, 
but alternatively, the PD-L1 expression might refl ect the adaptation of the tumor to 
the anti-tumor immune response, a process termed adaptive resistance.44 Several 
studies have investigated possible correlation of the expression of PD-1, PD-L1 
and/or PD-L2 with patient prognosis, as reviewed by Sznol et al.45 Because of 
the large variation and sometimes even opposite outcomes, these correlation 
studies should be interpreted with caution. Accumulating data from in vitro cell 
culture systems and animal models —indicating that PD-1/PD-L interactions form 
a major suppression mechanism within the tumor microenvironment— created the 
rationale to develop antibodies against PD-1 and PD-L1 for cancer immunotherapy. 
Figure 3. PD-1/PD-L pathway disrupts the anti-tumor T-cell response. Dendritic cells present tumor 
antigen to T cells to generate tumor-specifi c effector T cells. Both TCR-mediated signals and CD28 
costimulation are necessary for optimal anti-tumor T-cell responses. Upon recognition of tumor antigen 
on tumor cells, the effector CD8+ T cell will secrete toxicity mediators perforin and granzymes to kill 
the tumor cell. Ligation of PD-1 causes the recruitment of phosphatase SHP-2 that disrupts the TCR 
and CD28 signaling pathway through direct dephosphorylation of signaling intermediates. Enhanced 
PD-1/PD-L expression results in inhibition of T-cell priming in the tumor draining lymph node. Tumors 
that express PD-L1 are able to defend themselves against the attacks of effector T cells, as they can 
trigger the PD-1 molecule on these T cells and thereby downregulate the effector functions of the T 

















Initial clinical studies using these antibodies demonstrated remarkable anti-tumor 
activity,45;46 validating the PD-1/PD-L pathway as target for cancer immunotherapy.
PD-1 EXPRESSION IN NODAL T-CELL NON-HODGKIN LYMPHOMA
Gene expression profi ling analysis aimed to compare angioimmunoblastic T-cell 
lymphoma (AITL) with peripheral T-cell lymphoma, not otherwise specifi ed (PTCL–
NOS) clearly demonstrated that tumor cells in AITL show overexpression of several 
genes characteristic of normal TFH cells, such as PDCD1 (encoding PD-1), BCL6 
and CXCL13. These fi ndings strongly support that the TFH cell represent the cell 
of origin of AITL.47 Multiple immunohistochemical studies on AITL specimens 
confi rmed the (co)expression of one or more TFH markers.48-56 The pattern of 
PD-1 reactivity ranged from focal areas of increased numbers of extrafollicular 
T cells (usually less than 5% of interfollicular cells) to paracortical and diffuse 
reactivity throughout the lesion. PD-1+ cells were particularly enriched in areas 
unassociated with lymphoid follicles. The knowledge that AITL arise from these 
TFH cells provides a rational model to explain several of the peculiar pathological 
and biological features inherent to this disease, i.e. the expansion of B cells, the 
intimate association with germinal centers in early disease stages and the striking 
proliferation of follicular dendritic cells.
Apart from the cases which display peculiar pathological and biological features 
of AITL, some PTCL–NOS cases showed the expression of TFH markers and may 
be related to or derived from TFH cells. However, whether nodal follicular PTCL 
represents an early form of AITL or a distinct entity is unclear.57-59 PD-1 is not or 
rarely expressed on other types of T-cell non-Hodgkin lymphoma (NHL), such as 
anaplastic large cell lymphoma (ALCL) (Table 3).53-55;60
PD-1 EXPRESSION IN NODAL B-CELL NON-HODGKIN LYMPHOMA
Several studies investigated PD-1 expression in nodal B-cell NHL, demonstrating 
that chronic lymphocytic leukemia (B-CLL) was the only subtype in which the 
malignant B cells exhibited PD-1 positivity in almost all cases.53;61 The strongest PD-1 
staining was found in large para-immunoblasts and prolymphocytes located within 
proliferation centers, whereas small B cells in the surrounding areas showed less 
positivity. PD-1 is rarely expressed by the neoplastic B cells in follicular lymphoma 
and diffuse large B-cell lymphoma. 51;53;61 Other subtypes of B-cell NHL exhibit no 

















Table 3. PD-1 expression nodal T-cell non-Hodgkin lymphoma
Lymphoma type Xerri et al. 
2008
Yu et al. 
2009
Krishnan et al. 
2010











Peripheral T-cell lymphoma, 










B-cell NHL also comprise a variable proportion of PD-1+ reactive T cells,61-65 
showing signifi cantly higher numbers of PD-1+ lymphocytes in follicular lymphoma 
than in diffuse large B-cell lymphoma.61;62 Several studies reported that increased 
numbers of PD-1+ T cells in nodal follicular B-cell lymphoma are associated with 
signifi cantly improved survival, while in contrast, one other study showed that PD-1 
positivity is associated with a poorer outcome.61-64
PRIMARY CUTANEOUS LYMPHOMA
Defi nition
The term “primary cutaneous lymphoma’’ refers to a heterogeneous group of 
different T-cell and B-cell NHL that present in the skin without evidence of extra 
cutaneous involvement at the time of the diagnosis. It is important to differentiate 
these cutaneous T-cell lymphoma (CTCL) and cutaneous B-cell lymphoma (CBCL) 
from their nodal counterparts since they often have a completely different clinical 
behavior and prognosis and most often require different treatment modalities.
According to the World Health Organization – European Organization for 
Research and Treatment of Cancer (WHO-EORTC) classifi cation,66 primary 
cutaneous lymphoma are subdivided into the two main categories primary CTCL 
(75–80%) and primary CBCL (20–25%). Within the CTCL category the most common 
subgroups are: (1) the group of classical CTCL, including mycosis fungoides (MF), 
variants of mycosis fungoides and Sézary syndrome (SS); (2) the group of primary 
cutaneous CD30+ lymphoproliferative disorders (CD30+ LPD); (3) the group of rare 
and often aggressive cutaneous T/NK-cell lymphoma (Table 4). Within the CBCL 
category three main types of CBCL are described: primary cutaneous marginal 
zone lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL) and 

















PD-1 expression in primary cutaneous T-cell lymphoma
Recent studies reported PD-1 expression in MF, SS and primary cutaneous small/
medium sized pleomorphic T-cell lymphoma. In the following paragraphs these 
entities will be discussed and the potential signifi cance of investigating PD-1 
expression in these conditions will be presented.
• Mycosis fungoides
MF is the most common type of the CTCL, which mainly affects adults and accounts 
for almost 50% of all primary cutaneous lymphoma. MF is clinically characterized 
by the slow progression from patches to plaques, and even to tumors and in some 
cases may develop extracutaneous disease.66 
Histologically, the early stages of classic MF show superfi cial band-like 
or lichenoid infi ltrates with atypical small- to medium-sized T cells with highly 
convoluted (cerebriform) and hyperchromatic nuclei. These atypical T cells 
might infi ltrate into the epidermis (epidermotropism). With progression to 
tumor stage, the dermal infi ltrates become more diffuse, with an increase in the 
proportion of tumor cells, as well as an increase in the number of blast cells, and 
the epidermotropism might disappear. The neoplastic T cells in MF commonly 
show a CD4+CD8– phenotype, but may exhibit a CD4–CD8+ phenotype in some 
cases. Demonstration of an aberrant phenotype (for example, loss of pan–T-cell 
antigens, such as CD2, CD3, and CD5) is an important adjunct in the diagnosis 
of MF. Although MF commonly runs an indolent course, patients developing skin 
tumors, extracutaneous involvement or erythroderma may have a more unfavorable 
prognosis.
Wada et al. reported a percentage of more than 50% PD-1+ tumor cells in 6 of 
15 cases of patch/plaque stage MF (40%), 9 of 15 cases of tumor stage MF (60%), 
and in 8 of 11 biopsy specimens from patients with SS (63%).67 In the study of 
Kantekure et al. 16 of 26 MF biopsy specimens (62%) contained more than 25% 
PD-1+ tumor cells.68 In this latter study, the authors showed that PD-1 was more 
frequently expressed at the early patch and plaque stages of CTCL, while PD-1 
was expressed to a lesser extent at the tumor stage MF. Of note, this loss of 
PD-1 expression preferentially affected blast cells. Roncador et al. observed PD-1 
expression in 5 of 9 MF cases (56%).51
• Sézary syndrome
SS is a leukemic form of CTCL defi ned by erythroderma, lymphadenopathy 
and clonal CD4+ T cells in skin and blood (Sézary cells), and generally having a 

















palmoplantar hyperkeratosis and onychodystrophy might be seen. The diagnosis 
of SS can be challenging. Especially in the early stages of the disease, it can be 
diffi cult to differentiate SS from erythrodermic infl ammatory dermatoses (EID). 
Since the clinical presentation is generally not discriminative and histology may 
show reactive changes in up to one third of the cases, the diagnosis relies heavily on 
demonstration of neoplastic cells in the peripheral blood.69;70 In the WHO-EORTC 
classifi cation for cutaneous lymphoma published in 2005, and incorporated in the 
WHO classifi cation of lymphoid neoplasms in 2008, the diagnosis of SS is based 
on clinical presentation (erythroderma and lymphadenopathy) and demonstration 
of a T-cell clone in the peripheral blood (preferably the same clone in skin), in 
combination with one or more of the following criteria: an absolute Sézary cell 
count > 1000 cells per mm3; loss of T-cell markers CD2, CD3, CD4 and /or CD5 
and /or an expanding population of CD4+ T cells leading to a CD4/CD8 ratio of 
more than 10. Refs 58;66
Table 4. WHO-EORTC classifi cation of cutaneous lymphoma with primary cutaneous manifestations*
Cutaneous T-cell and NK-cell lymphoma
Mycosis fungoides
MF variants and subtypes
• Folliculotropic MF
• Pagetoid reticulosis
• Granulomatous slack skin
Sézary syndrome
Adult T-cell leukemia/lymphoma
Primary cutaneous CD30+ lymphoproliferative disorders
• Primary cutaneous anaplastic large cell lymphoma
• Lymphomatoid papulosis
Subcutaneous panniculitis-like T-cell lymphoma
Extranodal NK/T-cell lymphoma, nasal type
Primary cutaneous peripheral T-cell lymphoma, unspecifi ed
• Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma (provisional)
• Cutaneous / T-cell lymphoma (provisional)
• Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma (provisional)
Cutaneous B-cell lymphoma
Primary cutaneous marginal zone lymphoma
Primary cutaneous follicle center lymphoma
Primary cutaneous diffuse large B-cell lymphoma, leg type

















Samimi et al. found increased PD-1 expression in the peripheral blood neoplastic 
T cells in patients with SS, but not in the circulating T cells from patients with MF.71 
They observed a strong decrease in PD-1 expression along with improvement 
of disease. Moreover, an increase in interferon gamma production was found in 
cultures of PBMC from patients with SS if the PD-1/PD-L1 interaction was blocked 
by anti–PD-1 antibodies. They suggested that the high PD-1 expression may 
contribute to immunosuppression in SS, but mechanisms involved are as yet 
unknown.71
• Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma
Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma 
(PCSM-TCL) is a CTCL that is included as a provisional entity and rare subtype of 
primary cutaneous peripheral T-cell lymphoma, not otherwise specifi ed (PTCL–
NOS) in recent cutaneous lymphoma classifi cations (WHO-EORTC 2005; WHO 
2008).58;66 These PCSM-TCL characteristically present with a solitary plaque or 
tumor that is generally localized on the face or the upper trunk, and rarely with 
multiple papules, plaques or tumors.66;72;73 In particular patients presenting with a 
solitary skin lesion have an excellent prognosis.74 Histologically, these lymphoma 
show nodular to diffuse infi ltrates with a predominance of CD3+CD4+CD8–CD30– 
small/medium-sized pleomorphic T cells and a small proportion (<30%) of large 
CD4+ T cells. In most cases there is a considerable admixture with small reactive 
CD8+ T cells, CD20+ B cells, including some blast cells, histiocytes, and in some 
cases plasma cells and eosinophils. The clinical presentation, the architecture and 
cellular composition of these PCSM-TCL are strikingly similar to those described 
previously in so-called pseudo-T-cell lymphoma.75;76 The relationship between 
PCSM-TCL presenting with a solitary lesion and pseudo-T cell lymphoma and the 
most appropriate term for such lesions is a matter of debate.
These PCSM-TCL should be distinguished clinically and histologically from 
other types of CTCL, in particular PTCL–NOS and tumor-stage MF, as they have a 
completely different prognosis and require different types of treatment.74 Recently, 
Rodriguez-Pinilla et al. reported that medium-sized to large atypical CD4+ T cells 
in PCSM-TCL showed expression of PD-1, BCL6, CXCL13 and partially CD10, which 
suggested that these cells have a TFH cell phenotype.77
PD-1 expression in primary cutaneous B-cell lymphoma
In the classifi cation of WHO-EORTC (Table 4) three main types of CBCL are 
described: primary cutaneous marginal zone lymphoma (PCMZL), primary 

















B-cell lymphoma, leg type (PCLBCL–LT). PCMZL and PCFCL are indolent types 
of CBCL having excellent prognosis. PCLBCL–LT is an aggressive type of tumor 
with a 5-year survival of only circa 50%. Studies about PD-1 expression in CBCL is 
scarce. Rodriguez-Pinilla et al. reported negative staining for PD-1 in some cases 
of PCMZL and PCFCL.77 However, studies on the number and the distribution of 
reactive T-cells as performed in nodal B-NHL are lacking.
AIMS AND OUTLINE OF THE THESIS
Studies in this thesis were aimed to investigate whether the PD-1 molecule a useful 
marker in the diagnosis of different types of cutaneous lymphoma. In our fi rst study 
presented in Chapter 2 we investigated the expression of PD-1 and other TFH cell 
markers in a large group of patients with PCSM-TCL. The goal of this study was 
to determine whether PD-1 expression by atypical T cells could serve as a useful 
diagnostic marker to differentiate between PCSM-TCL and other types of CTCL. 
In this study we included skin biopsies from patients with MF, cutaneous ALCL and 
cutaneous PTCL–NOS.
The study described in chapter 2 revealed that PD-1 expression was detected 
on neoplastic cells in only 2 of 21 MF biopsy samples. This result is in contrast to 
published studies of other research groups, which reported that PD-1 expression is 
commonly seen in MF. Chapter 3 describes results of staining for PD-1 and other 
TFH markers (BCL-6,CXCL-13,CD10) in a large cohort of patients with MF, including 
patients with erythrodermic MF and SS. 
It is well-known that histologic differentiation between SS and erythrodermic 
infl ammatory dermatosis (EID) may be extremely diffi cult.78 In Chapter 4 we 
investigated the expression of PD-1 in skin biopsies of SS patients and patients 
with various types of EID. The main goal was to investigate if the number and 
distribution of PD-1+ T cells is useful as an adjunct in the differentiation between 
SS and EID.
In the continuous search for SS-specifi c diagnostic biomarkers, we explored in the 
study described in Chapter 5 the expression of two other potential diagnostic 
markers, using the same group of patients with SS or EID as presented in chapter 
4. These two markers are thymocyte selection-associated high mobility group 
box protein (TOX) and C-MYC, which is a transcription factor that regulates the 

















has been found in MF and SS, but information on TOX expression in EID is lacking. 
In addition, C-MYC positivity has been demonstrated in a considerable number of 
infi ltrating lymphoid cells in MF and SS, while there is no information on C-MYC 
expression in EID. We explored in this study if expression of TOX and C-MYC can 
also be used as diagnostic marker for the differentiation between SS and EID.
In Chapter 6, we investigated the expression of PD-1 in skin sections from primary 
CBCLs. The aim of this study was to fi nd out if PD-1 is expressed by the neoplastic 
B cells of these lymphoma. In addition, the number and distribution of PD-1+ T cells 
was investigated and correlated with clinical behavior. 
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In this study we investigated whether programmed death-1 (PD-1) could serve 
as useful diagnostic marker to differentiate between primary cutaneous CD4+ 
small/medium-sized pleomorphic T-cell lymphomas (PCSM-TCL) and cutaneous 
pseudo-T-cell lymphomas on the one hand and other types of cutaneous T-cell 
lymphomas (CTCLs) on the other. Formalin-fi xed, paraffi n-embedded skin biopsies 
from 26 patients with PCSM-TCL or pseudo-T-cell lymphoma, including 1 patient 
with a lymphomatoid drug eruption, and 52 skin biopsies from other types of 
CTCLs were stained for PD-1. In addition, PD-1 positive cases were stained with 
antibodies against BCL6, CXCL13 and CD10 to determine a possible relationship 
with follicular helper T (TFH) cells. In all 26 cases of PCSM-TCL or pseudo-T-cell 
lymphoma, the medium-sized to large-sized atypical T cells consistently expressed 
PD-1, BCL6 and CXCL13, but not CD10. PD-1 expression was found in only 2 of 21 
cases of mycosis fungoides and in only 2 of 16 cases of cutaneous peripheral T-cell 
lymphoma, unspecifi ed. All 4 patients with an aggressive epidermotropic cytotoxic 
CD8+ CTCL and all 11 cases with a primary cutaneous CD30+ lymphoproliferative 
disorder were negative for PD-1. In conclusion, PD-1 is typically expressed by the 
atypical cells in PCSM-TCL and pseudo-T-cell lymphoma, but is not expressed or 
is rarely expressed in other types of CTCLs. Therefore, it may serve as a suitable 
adjunct in differential diagnosis. Our results demonstrate that the atypical cells in 
PCSM-TCL and pseudo-T-cell lymphomas share a common TFH phenotype and 
support the view that most cases classifi ed nowadays as PCSM-TCL are identical 























Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma (PCSM-
TCL) is a cutaneous T-cell lymphoma (CTCL) that has been included as a provisional 
entity and rare subtype of primary cutaneous peripheral T-cell lymphoma, not 
otherwise specifi ed (PTCL–NOS), in recent cutaneous lymphoma classifi cations 
[World Health Organization–European Organization for Research and Treatment of 
Cancer (WHO-EORTC) 2005; WHO 2008].22, 24 These PCSM-TCLs characteristically 
present with a solitary plaque or tumor that is generally localized on the face or 
the upper trunk and rarely present with multiple papules, plaques, or tumors.3, 
10, 24 In particular, patients presenting with a solitary skin lesion have an excellent 
prognosis.2 Histologically, these lymphomas show nodular-to-diffuse infi ltrates 
with a predominance of CD3+, CD4+, CD8–, CD30– small-sized to medium-sized 
pleomorphic T cells and a small proportion (<30%) of large CD4+ pleomorphic T 
cells. In most cases there is a considerable admixture with small reactive CD8+ 
T cells and CD20+ B cells, including some blast cells, histiocytes, and in some 
cases plasma cells and eosinophils. The clinical presentation, the architecture, 
and cellular composition of these PCSM-TCLs are strikingly similar to those 
described previously in so-called pseudo-T-cell lymphomas.16, 17 Demonstration 
of a T-cell clone (common) and loss of pan-T-cell antigens (rare) are nowadays 
used as diagnostic criteria for PCSM-TCL,1 but delineation between PCSM-TCL and 
pseudo-T-cell lymphomas is arbitrary and a matter of debate.
Recently, Rodriguez-Pinilla et al. reported that the large atypical CD4+ T cells 
in PCSM-TCL express programmed death-1 (PD-1), BCL6 and CXCL13.18 PD-1, 
which is located on chromosome 2q37, is a member of the CD28/CTLA-4 receptor 
family that regulates cellular immune responses.7, 8 PD-1 has 2 known ligands called 
PD-L1and PD-L2. Engagement of PD-1 by its ligands inhibits T-cell activation and 
induces peripheral tolerance.12 PD-1 is constitutively expressed by a particular 
germinal center T-cell subset, called follicular helper T (TFH) cells. These TFH cells, 
which also highly express CXCL13 and BCL6,6 play an important role in germinal 
center formation and plasma cell development. The expression of PD-1, BCL6, and 
CXCL13 by the large atypical CD4+ T cells in PCSM-TCL suggests that this type of 
CTCL originates from TFH cells.18 Previous studies have also demonstrated a high 
expression of PD-1,13, 19, 25, 26, 28 CXCL13,19, 26, 28 BCL6,19, 27, 28 and CD1027, 28 by neoplastic 
T cells in angioimmunoblastic T-cell lymphoma (AITL), and AITL is now commonly 
considered as a tumor of TFH cells.
PCSM-TCL should be distinguished histologically not only from pseudo-T-cell 
lymphomas but also from other types of CTCLs, in particular PTCL–NOS and tumor-
stage mycosis fungoides (MF). In rare cases with scattered CD30+ blast cells, a 
diagnosis of primary cutaneous CD30+ lymphoproliferative disease may even be 






















may be misdiagnosed as cutaneous lymphoid hyperplasia or cutaneous marginal 
zone B-cell lymphoma. Differentiation between PCSM-TCL and these other types 
of CTCLs is extremely important, as they have a completely different prognosis 
and require different types of treatment.2 Studies on PD-1 expression in PTCL–NOS 
are few and showed confl icting results, with percentages of PD-1-positive cases 
varying between 0% and 71%.13, 15, 25, 26, 28 A recent study reported expression of 
PD-1 in skin biopsies of 15 of 30 cases (50%) of MF and 8 of 11 cases (73%) of Sézary 
syndrome.23 Another study also found increased PD-1 expression by the circulating 
neoplastic T cells in Sézary syndrome and suggested that PD-1 may contribute to 
immunosupression.20
The aim of this study was to determine whether PD-1 could serve as a useful 
diagnostic marker to differentiate between PCSM-TCL and other types of CTCLs. 
In addition, we also investigated all PD-1-positive cases for expression of BCL6, 
CXCL13, and CD10 to determine whether these cells have a TFH-cell phenotype. 
MATERIALS AND METHODS
Patients
Paraffi n-embedded skin biopsies from 26 patients with a PCSM-TCL or with a 
pseudo-T-cell lymphoma (further collectively termed PCSM-TCL; see Discussion 
section) were selected from the cutaneous lymphoma database of the Leiden 
University Medical Center. This group included 1 patient with a lymphomatoid drug 
eruption reported previously.16 In addition, 10 patients with patch/plaque-stage MF, 
11 patients with tumor-stage MF, 16 patients with a primary (n = 9) or secondary (n 
= 7) cutaneous PTCL–NOS, 4 patients with an aggressive epidermotropic cytotoxic 
CD8+ CTCL, which is another rare subtype of PTCL, and 11 with a primary cutaneous 
CD30+ lymphoproliferative disorder, including 5 patients with lymphomatoid 
papulosis and 6 cases with a primary cutaneous anaplastic large cell lymphoma 
(C-ALCL), were studied. In all cases the diagnosis was based on the criteria of 
the WHO-EORTC classifi cation for primary cutaneous lymphomas24 and had been 
confi rmed by an expert panel of dermato(patho)logists and hematopathologists 
of the Dutch Cutaneous Lymphoma group.
Immunohistochemistry
Sections of formalin-fi xed, paraffi n-embedded tissue were dried overnight (37°C) 
and subsequently dewaxed and rehydrated. Endogenous peroxidase activity was 
blocked by incubation with 0.3 % hydrogen peroxide in methanol. After antigen 
retrieval by boiling for 10 min in 10 mmol/L citrate buffer (pH 6.0), tissue sections 






















antibody AF1086), CXCL13 (1:400, goat polyclonal antibody AF801), both purchased 
from R&D Systems (Abingdon, UK), or BCL6 (1:50, monoclonal M-7211) from Dako, 
Glostrup, Denmark. The PD-1 and CXCL13 sections were then incubated with a 
Goat HRP-Polmer Kit from Biocare Medical (Concord, CA). The BCL6 sections 
were incubated with a BrightVision Poly-HRP Kit from Immunologic (Duiven, The 
Netherlands). Immunoreactivity was detected using diaminobenzidine reagents, 
and counterstaining was performed with Mayer haematoxylin. Detection of CD3, 
CD4, CD8, CD10, CD20, CD68, CD79a, and MIB-1 was performed by routine 
immunostaining. Human tonsil and 3 cases of AITL were used as positive controls 
for PD-1, BCL6, and CXCL13 stainings. Negative controls were obtained by omitting 
the primary antibody.
T-cell Clonality Studies
Polymerase chain reaction was performed to analyze the clonal expansion of T cells. 
DNA was extracted from paraffi n sections, and T-cell clonality was detected by 
analysis of T-cell receptor (TCR)  (V-J and D-J) and TCR gene rearrangement, 





The study group contained 18 male and 8 female patients with a median age of 
55 years at presentation (range, 5 to 88 years). None of the 26 patients had skin 
lesions or a history suggestive of MF, lymphadenopathy, or B symptoms. One 
of these patients presented with 3 slightly scaling plaques on the trunk while 
using carbamazepine. As discontinuation of the antiepileptic drug resulted in 
complete clearance of the skin lesions, a diagnosis of lymphomatoid drug eruption 
was considered most likely.16 The etiology in the other 25 patients is unknown. 
Altogether, 23 of 26 patients presented with a solitary plaque or tumor (Figures 1A 
and 2A), which was preferentially localized on the head/neck (n = 7) or upper trunk 
(n = 14). Only 3 of 26 patients presented with multiple skin lesions. Routine physical 
and laboratory examinations showed no abnormalities in any case. Additional 
imaging studies had been conducted in only 4 patients and had not shown any 
abnormalities. In most cases treatment consisted of topical or intralesional steroids 
(n = 10) or excision (n = 11), whereas 1 patient was treated with radiotherapy. 
Spontaneous remission after the diagnostic skin biopsy or after discontinuation of 






















topical steroids were observed in 4 patients, 1 of them with multiple skin lesions. 
After a median follow-up of 10 months (range, 2 to 108 months), 23 patients are 
in complete remission, and 3 patients are alive with disease. None of the patients 
have developed extracutanous disease.
Histology 
Eleven cases, including the lymphomatoid drug eruption, showed a dense 
subepidermal band-like infi ltrate, which characteristically showed a sharp 
demarcation at the lower border, which sometimes extended around hair follicles 
(Figures 1B and C). Fifteen cases showed a nodular-to-diffuse infi ltrate throughout 
the entire dermis, often extending into the subcutaneous fat (Figures 2B and C). 
In both groups, infi ltration of the epidermis or follicular structures was either not 
present or only focally present. The cellular composition of both groups was also 
highly similar. In all cases, the infi ltrates were predominantly composed of small/
medium-sized lymphocytes with variable numbers (5 to 25%) of medium-sized to 
Figure 1. A PCSM-TCL patient with a superfi cial band-like pattern. (A) Patient presenting with 
a solitary plaque on the upper back. (B) Histologically, there is a subepidermal, band-like infi ltrate. 
Panel C is a higher magnifi cation of the indicated area depicted in panel B, showing medium-sized to 
large atypical cells (arrowheads). The atypical cells express CD4 (D), PD-1 (E), BCL6 (F), and CXCL13 
as perinuclear dots (see inset) (G). The insert at the bottom of E is a higher magnifi cation of the area 






















Figure 2. A PCSM-TCL patient with a nodular pattern. (A) Patient presenting with a tumor on the left 
temple (B) Histologically, the lesion shows a nonepidermotropic nodular infi ltrate throughout the entire 
dermis. Panel C is a higher magnifi cation of the marked area in panel B, showing many medium-sized to 
large atypical cells (arrowheads), which express CD4 (D). There is a considerable admixture with reactive 
CD8+ T cells (E), CD20+ B cells (F), and CD68+ histiocytes (G). The medium-sized to large atypical T 
cells express PD-1 (H), BCL6 (I) and CXCL13 (J). The insert at the bottom of H is a higher magnifi cation 






















large lymphoid cells with hyperchromatic and irregular nuclei and scattered blast 
cells (Figures 1C and 2C). Scattered mitotic fi gures were observed. In all cases 
there was a considerable admixture with histiocytes, and in some cases were 
accompanied by multinucleated giant cells and/or granulomatous changes. Plasma 
cells were generally present (in 3 cases even in large numbers), but eosinophils 
were few or absent.
Immunohistochemistry
In all cases, the medium-sized and large atypical cells, varying between 5% and 
25% of the total infi ltrate, showed a CD3+, CD4+, CD8– T-cell phenotype without 
loss of CD2 or CD5 (Figures 1D and 2D). In all cases there was a considerable 
admixture with reactive CD8+ T cells (median, 20%; range, 5% to 30%), scattered 
or clustered CD20+ and/or CD79a+ B cells, including a few blast cells (median, 15%; 
range, 5% to 30%), and CD68+ histiocytes (median, 15%; range, 5% to 20%) (Figures 
2E–G). Cytotoxic proteins were not expressed. CD30+ blast cells were generally 
few (< 5%). The proliferation rate varied between < 5% and 20% (median, 10%). 
MIB-1 was predominantly expressed by the large atypical cells. In all 26 cases the 
medium-sized to large atypical T cells consistently expressed PD-1, BCL6 and 
CXCL13 (Figures 1E–G and Figures 2H–J). In all 12 cases the CD10 staining was 
negative. Serial sections showed that CXCL13 generally stained 50% to 75% of 
PD-1+ cells, and BCL6 stained 25% to 50% of PD-1+ cells. In addition to the medium-
sized to large atypical T cells, a few small reactive T cells showed a positive staining 
for PD-1, BCL6, and CXCL13. The neoplastic cells of the 3 AITL cases included 
as a positive control consistently expressed PD-1, BCL6, CXCL13, and CD10.
Molecular studies
Multiplex polymerase chain reaction analysis using the BIOMED-2 protocol 
demonstrated clonal TCR gene rearrangement in 16 cases, including the case with 
a lymphomatoid drug eruption, an oligoclonal pattern in 1 case, and an absence 
of clones in 5 cases. In 4 cases, evaluation was impossible because of poor DNA 
quality or lack of material. 
PD-1 staining in other CTCLs
PCSM-TCL with a nodular or diffuse pattern resemble cutaneous PTCL–NOS and 
tumor-stage MF, whereas PCSM-TCL with a band-like pattern resemble patch/
plaque-stage MF.1, 16, 17, 21 Skin sections from both plaque-stage and tumor-stage 
MF and from patients with cutaneous PTCL–NOS were therefore stained for PD-1 
to determine whether this molecule is differentially expressed in these lymphomas. 
Because of the presence of scattered CD30+ cells in most PSCM-TCLs, which may 






















patients with lymphomatoid papulosis (LyP) and 6 patients with a C-ALCL were 
selected as well.
The neoplastic cells in all 21 MF lesions had a CD3+, CD4+, CD8– T-cell phenotype 
with frequent loss of pan-T-cell antigens in tumorous lesions (Figures 3A and B). In 
only 1 of 10 plaques and 1 of 11 tumorous lesions did virtually all neoplastic cells 
express PD-1 (Figure 3D). In both cases, BCL6 and CXCL13 were expressed by 25% 
to 50% of PD-1+ cells (Figures 3E and F), whereas CD10 was strongly expressed by 
the neoplastic T cells in 1 of these 2 cases (Figure 3C). In the other 19 MF biopsies, 
PD-1, BCL6, and CXCL13 only stained a few small reactive T cells.
Routine immunophenotypical studies in the PTCL–NOS group showed that 
8 cases had a CD3+, CD4+, CD8– T-cell phenotype, 4 cases a CD4–, CD8– T-cell 
phenotype and 4 cases a CD4–, CD8+ T-cell phenotype. In contrast to the group 
of PCSM-TCLs, in most cases there was loss of 1 or more pan-T-cell antigens, a 
minimal admixture with infl ammatory cells, and a proliferation rate of more than 
50%. In only 2 cases, both secondary cutaneous CD4+ PTCL–NOS, did neoplastic 
T cells weakly stain for PD-1, BCL6, and CXCL13 but not for CD10. In the other 
cases, PD-1, BCL6, and CXCL13 only stained a few scattered reactive T cells. The 
neoplastic CD8+ T cells in 4 patients with an aggressive CD8+ epidermotropic 
cytotoxic CTCL did not express PD-1.
Figure 3. Mycosis fungoides. (A) Haematoxylin-eosin staining of a skin lesion from a patient with 
plaque-stage MF showing a dense infi ltrate in the papillary dermis. The insert at the bottom is a 
higher magnifi cation of the area indicated in the papillary dermis. There is extensive infi ltration in the 
epidermis with formation of Pautrier microabscesses. The neoplastic cells expressed CD3 (B), CD10 






















Consistent with previous studies, the large atypical CD30+ cells in skin lesions 
of 11 patients with LyP (n = 5) or C-ALCL (n = 6) were consistently negative for 
PD-1. PD-1 expression in the different types of CTCLs are summarized in Table 1.
DISCUSSION
In this study, the medium-sized to large atypical CD4+ T cells in all 26 cases of 
PCSM-TCL consistently showed expression of PD-1, BCL6, and CXCL13, which 
confi rms the results of a previous study and suggests that these cells have a TFH 
cell phenotype. In contrast to AITL,27 now commonly considered as a tumor of TFH 
cells, CD10 was not expressed in any of the 11 PSCM-TCLs studied. In the study 
by Rodriguez-Pinilla et al., CD10 was expressed by a proportion of the atypical T 
cells in 3 of 15 cases.18 Interestingly, in our study PD-1 expression was found in 
only 2 of 16 PTCL–NOS, both cases with secondary cutaneous involvement, and 
not in the 4 aggressive epidermotropic cytotoxic CD8+ CTCLs. Our observations 
are consistent with other studies in PTCL–NOS, in which no25, 26 or a single case15 
showed PD-1 positivity but are in contrast with another study in which 10 of 14 
cases expressed PD-1.13 Moreover, in our study, PD-1 expression was found in 
only 2 of 21 cases of MF, including 1 of 10 plaque-stage and 1 of 11 tumor-stage 
MFs. Both cases also expressed BCL6 and CXCL13, whereas CD10 was strongly 
expressed in only 1 of them. A recent study reported expression of PD-1 in 6 of 
15 (40%) skin biopsies of patch/plaque-stage MF and 9 of 15 (60%) biopsies of 
tumor-stage MF.23 An explanation for these discrepant results is currently lacking. 
Consistent with previous studies, PD-1 was not expressed by the large CD30+ cells 
in LyP or C-ALCL.13, 25, 26
The differences in PD-1 expression between PCSM-TCL on the one hand and 
cutaneous PTCL–NOS and tumor-stage MF on the other hand indicate that a 
positive staining of this marker may be used as an additional criterion to differentiate 
PCSM-TCL from these other types of CTCLs. This is particularly important in cases 
presenting with a solitary tumor, which was observed in all but 3 cases of PCSM-TCL 
and also in 4 patients with a primary cutaneous PTCL–NOS, all being negative for 
PD-1. In contrast to the patients with a PCSM-TCL, 3 of these 4 patients died of 
their disease 8 to 12 months after diagnosis, whereas 1 recently diagnosed patient 
is still alive with disease 5 months after diagnosis.
PCSM-TCL or cutaneous pseudo-T-cell lymphoma?
In this study, the group of PCSM-TCL contained cases that might be classifi ed 
either as PCSM-TCL or as pseudo-T-cell lymphoma. The relationship between both 
conditions is a matter of debate. In the 1990s we and others introduced the term 





















Abut with a clinical presentation and clinical course more consistent with a benign 
condition.16, 17, 21 Prototypic patients were those using anti-epileptic drugs and 
presenting with a solitary plaque or nodule, which showed an atypical band-like 
subepidermal infi ltrate mimicking MF. The correct diagnosis in such patients is a 
lymphomatoid drug eruption. For skin lesions showing the same atypical band-like 
infi ltrate, but without known cause (most of them), the term pseudo-T-cell lymphoma 
was used.16, 17, 21 In addition to cases with a superfi cial band-like infi ltrate, other 
patients presenting with a solitary plaque or nodule showed a nodular-to-diffuse 
infi ltrate, which sometimes extended into the subcutaneous fat. Apart from the 
difference in architecture (band-like versus nodular to diffuse), these pseudo-T-cell 
lymphomas with a nodular-to-diffuse growth pattern showed the same clinical 
presentation and clinical course and had the same cellular composition as the 
cases with a band-like infi ltrate: an atypical infi ltrate with a predominance of small/
medium-sized lymphocytes with variable numbers (but always < 30%) of medium-
sized to large CD3+, CD4+, CD8– T cells, a considerable admixture with CD8+ T 
cells, CD20+ B cells, and histiocytes, a low proportion of proliferating cells, and no 
or only focal infi ltration of the epidermis or follicular epithelium.16
In our initial studies, using Southern blot analysis, no clonality was found, and 
absence of clonality and absence of marker loss were suggested as useful criteria to 
differentiate these pseudo-T-cell lymphomas from MF and from primary cutaneous 
PTCL–NOS.1
With the introduction of new and more sensitive techniques to demonstrate 
T-cell clonality it has become clear that most cases until then classifi ed as pseudo-
T-cell lymphoma contain clonal T cells. In addition, clonal T cells can also be 
found in lymphomatoid drug eruptions,5, 11, 14 as illustrated by the patient with a 
carbamazepine-associated lymphomatoid drug eruption in this study. In cases 
Table 1. PD-1 Expression in Different Types of Cutaneous T-cell Lymphoma
 Cases With Neoplastic PD-1+ Cells
Type of Lymphoma  Number   Neoplastic T cells      Percentage



















Aggressive CD8+ epidermotropic cytotoxic CTCL 4 – 0
Primary Cutaneous CD30+ lymphoproliferative disorders
Lymphomatoid papulosis




























in which a cause is known or presumed, and more in general in cases with an 
atypical band-like infi ltrate confi ned to the papillary dermis, a diagnosis of pseudo-
T-cell lymphoma or atypical lymphoid hyperplasia is often preferred, despite the 
detection of clonal T cells. However, in cases with a nodular-to-diffuse infi ltrate, in 
which generally no causal factor can be detected, demonstration of T-cell clonality, 
in combination with a sometimes highly atypical morphology, nowadays generally 
results in a diagnosis of PCSM-TCL.
In this study, using the BIOMED-2 protocol, clonal TCR gene rearrangements 
were detected in 8 of 10 cases with a band-like pattern and 9 of 12 cases with 
a nodular-to-diffuse pattern. Both histologic groups had an identical cellular 
composition and in both groups the medium-sized to large atypical CD4+ T cells 
consistently expressed PD-1, BCL6, and CXCL13. In our view, there is therefore 
no reason to classify these two groups separately. Whether all cases should be 
classifi ed as PCSM-TCL or as pseudo-T-cell lymphoma is a matter of debate. The 
overlapping features between PCSM-TCL and pseudo-T-cell lymphomas are widely 
recognized. Since differentiating criteria are lacking, Cerroni suggested the term 
“cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined 
signifi cance”, and emphasized that these cases should not be treated aggressively.3 
Most cases in our study were still classifi ed as pseudo-T-cell lymphoma or as 
“spectrum of pseudo-T-cell lymphoma/PCSM-TCL”. Regardless of the term 
preferred, there is consensus that patients presenting with a solitary lesion and the 
characteristic histologic and immunophenotypical features described herein have 
an excellent prognosis. In our department, staging procedures are generally not 
performed in these patients, and their skin lesions, if not resolved spontaneously 
after skin biopsy, are treated with intralesional steroids or surgical excision and 
only by exception with radiotherapy. As in other pseudolymphomas, we advise a 
follow-up period of two years. The fact that all patients had an uneventful follow-up 
and that a skin relapse was observed in only 4 of 26 cases suggest that this is a 
correct and safe approach. 
PCSM-TCLs that do not meet the criteria of the cases described herein are 
rare and should be fully staged. A recent study suggesting that PCSM-TCLs with 
rapidly growing bulky tumors, a low percentage of admixed CD8+ T cells, and/
or a high proliferative fraction are at risk to develop progressive disease awaits 
further confi rmation.9 Whether such cases have also a TFH phenotype remains to 
be established.
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Objective: To determine if there are differences in the expression of programmed 
death-1 (PD-1)  between Sézary syndrome (SS) and mycosis fungoides (MF), and 
in particular erythrodermic MF (E-MF). PD-1 is a marker of follicular helper T (TFH) 
cells and is expressed by the neoplastic T cells of some types of malignant T-cell 
lymphoma, including SS and MF. Reported results of PD-1 staining in SS and MF 
are, however, confl icting. 
Design: Formalin-fi xed, paraffi n-embedded skin biopsy specimens were stained for 
PD-1. In addition, PD-1+ cases were stained with antibodies against BCL6, CXCL13, 
and CD10 to fi nd possible relationship with TFH cells.
Setting: Tertiary referral center for cutaneous lymphomas. 
Patients: Twenty-seven patients with SS and 60 patients with MF, including eight 
patients with E-MF. 
Results: In patients with SS, expression of PD-1 by more than 50% of the neoplastic 
T cells was observed in 24 of 27 cases (89%). In contrast, PD-1 expression by more 
than 50% of neoplastic T cells was found in only 8 of 60 patients with MF (13%), 
including only 1 of 8 patients with E-MF (12%). In PD-1+ cases, serial skin sections 
showed that CXCL13 and BCL6 generally stained 25% to 50% of the PD-1+ cells, 
while expression of CD10 was uncommon. 
Conclusions: The results of the present study show differential expression of PD-1 
between SS and MF/E-MF, which provides further support for the view that SS and 

























Recent studies described the expression of membrane molecule programmed 
death-1 (PD-1; CD279) by the neoplastic T cells of various types of malignant T-cell 
lymphomas, including Sézary syndrome (SS) and mycosis fungoides (MF).1-6 PD-1 
belongs to the CD28/CTLA-4 receptor family and has a key role in regulating 
cellular immune responses.7;8 PD-1 has 2 identifi ed ligands called PD-L1 (CD274), 
which has a broad expression profi le, including non-immune cells, and PD-L2 
(CD273), which is found primarily on activated professional antigen-presenting 
cells.7;8 Engagement of PD-1 with its ligands has been shown to inhibit T-cell 
activation and proliferation.9 Since loss of PD-1 is associated with the development 
of autoimmune diseases, PD-1 is considered to play an important role in peripheral 
tolerance.7;8 Whereas activation is necessary to induce PD-1 expression by T cells, 
B cells, and dendritic cells,8 some cell types, such as follicular helper T (TFH) cells, 
have a constitutive high expression of PD-1.10 TFH cells, which also highly express 
chemokine (C-X-C motif) ligand 13 (CXCL13) and B-cell lymphoma 6 (BCL6), are 
localized in the lymph node follicles and provide essential support to germinal 
center formation and plasma cell development. 
Recent studies showed that the neoplastic cells in angioimmunoblastic T-cell 
lymphoma (AITL) express PD-1, CXCL13, BCL6 and CD10.1;3 Because of this 
phenotypically resemblance to TFH cells, AITL is now commonly considered to 
be a tumor of TFH cells. More recently, we and others reported that the atypical 
medium- to large-sized CD4+ T cells in primary cutaneous CD4+ small/medium-
sized pleomorphic T-cell lymphoma (PCSM-TCL) also express PD-1. Since 25% to 
75% of these PD-1+ cells also express CXCL13 and BCL6, it has been suggested that 
this type of cutaneous T-cell lymphoma (CTCL) may also originate from TFH cells.11;12
Samimi et al. found increased PD-1 expression in the circulating neoplastic T cells 
in patients with SS, but not in CD4+ peripheral blood T cells from patients with MF 
or healthy controls, and suggested that PD-1 may contribute to immunosuppression 
in SS.5 In other studies, PD-1 expression by the neoplastic T cells was found in 50% 
to 60% of skin biopsy samples of patients with MF and 73% of skin biopsy samples 
of those with SS.6;13;14 In contrast, in our recent study on PCSM-TCL, PD-1 expression 
was detected in only 2 of 21 MF biopsy samples, included as a control group.12 
These discrepant results prompted us to investigate PD-1 expression in a large 
group of biopsy samples obtained from patients with SS and those with different 
stages of MF. In addition, we also investigated all PD-1+ cases for expression of 
BCL6, CXCL13, and CD10 to determine if these cells have a TFH cell phenotype. 
Our results show differential expression of PD-1 in SS and MF, which provides 


























Paraffi n-embedded skin biopsy specimens from 27 patients with SS and 60 patients 
with MF were selected for this study. All skin samples were collected from the 
archives of the Department of Pathology, Leiden University Medical Center (LUMC) 
according the “Dutch Code for Proper Secondary Use of Human Tissue”, which is 
approved by the Medical Ethics Committee of the LUMC. In some patients, multiple 
skin biopsy specimens obtained from different stages of disease or during follow-
up, and additional biopsy specimens from involved lymph nodes were studied. All 
cases had been reviewed by an expert panel of dermatologists and pathologists 
during one of the quarterly meetings of the Dutch Cutaneous Lymphoma group, 
and were classifi ed according to the criteria of the World Health Organization 
– European Organization for Research and Treatment of Cancer (WHO-EORTC) 
for primary cutaneous lymphomas.15 Stage of disease was based on the revised 
International Society for Cutaneous Lymphomas/EORTC criteria.16 All patients 
with SS had erythroderma and peripheral blood involvement at fi rst presentation 
(T4N0-3B2). Twenty-fi ve of 27 patients with SS showed clonal T-cell receptor gene 
rearrangement in combination with a CD4/CD8 ratio more than 10 (range, 12 – 232) 
in the peripheral blood. In the other 2 patients, peripheral blood involvement was 
confi rmed by the presence of a T-cell clone in combination with either a CD4+/
CD7– ratio greater than 40 or the presence of more than 1000 Sézary cells/mm3.
The MF group included 30 biopsy specimens from patients with patches or 
plaques (stage IA-IB), 22 biopsy specimens from skin tumors (19 from patients 
with stage IIB disease, 3 from patients with stage IV) and 8 biopsy specimens 
from patients with E-MF (3 patients with stage III disease; 5 patients with stage IV). 
Twenty-one of these 60 skin biopsy specimens were included in a previous study, 
where they served as a control group.12 With respect to the E-MF group, 5 patients 
had a history of classical (folliculotropic) MF and developed E-MF with (cases 2 – 4) 
(Table 1) or without (cases 1 and 5) (Table 1) peripheral blood involvement 24 to 
240 months after initial diagnosis, while 3 presented with erythroderma with the 
histologic features of MF, but without peripheral blood involvement (cases 6 – 8) 
(Table 1). Since the defi nition and terminology of cases with E-MF is subject to 
debate, the main features of these 8 cases have been summarized in Table 1.
Histologic and immunohistochemical analysis
In sections from all biopsy specimens, we routinely performed hematoxylin-eosin 
stainings and immunostainings to detect T-cell–associated antigens (CD2, CD3, 
























antigens (CD68) and CD30. Sections from all patients were stained for PD-1, and 
in addition, PD-1+ cases were also stained for BCL6, CXCL13, and CD10. Staining 
procedures for PD-1 (1:200, goat polyclonal antibody AF1086) and CXCL13 (1:400, 
goat polyclonal antibody AF801), both purchased from R&D Systems (Abingdon, 
UK), and BCL6 (1:50, monoclonal M-7211) from Dako, (Glostrup, Denmark) have 
been previously described.12 The percentage of PD-1+ neoplastic T cells was scored 
as less than 10%, 11% to 25%, 26% to 50%, and more than 50%. A case was 
considered PD-1+ when more than 50% of the neoplastic T cells were stained.
Statistic analysis
Statistical calculations were performed using SPSS statistical software (version 
17.0) (SPSS Inc., Chicago, IL). Comparison of PD-1 expression between SS and MF 
(including E-MF) and SS and MF was performed using the Fisher exact test. All 
p-values were 2-tailed and p < 0.05 was considered statistically signifi cant.



















1A/F/67 IB (T2N0B0) – ND ND ND ND
1B/F/74 IVA (T4N3B0) – 2 – – – 96
2A/M/51 IB (T2N0B0) + ND ND >75 ND
2B/M/71 IVA (T4N0B2) + 35 + >75 ND 240
3A/F/60 IB (T2N0B0) + ND ND – ND
3B/F/64b IVA (T4NxB2) + 40 + – ND 48
4A/M/50 IIA (T2N2B0) + 9 ND ND ND
4B/M/52 IVA (T4N2B2) + 20 + <10 ND 24
5A/M/58 IB (T2N0B0) – ND ND ND ND
5B/M/63 III (T4N3B0) – 2 – – – 64
6AB/M/76b III (T4N3B0) – 1 – <10 – 0
7AB/M/64 III (T4N1B0) – 13 – – ND 0
8AB/M/62 IVA (T4N3B0) + 2 ND 10-15 <5
8FU/M/63b IVA (T4N3B2) + 12 + 10-15 ND 0
Abbreviations: FU, follow-up; ND, no data; PD-1, programmed death-1; +, positive; –, negative
a A: at time of fi rst diagnosis: B: at time of E-MF; AB: E-MF at presentation


























Routine immunostaining revealed a CD3+, CD4+, CD8– mature T-cell phenotype in 
all SS cases. Marker loss of either CD2, CD3, or CD5, defi ned as absent staining 
by more than 50% of the neoplastic T cells, was detected in only 1 of 27 SS cases 
(3.7%), in which the neoplastic cells lacked CD2. In 2 other cases there was partial 
loss (< 50% loss) of either CD3 or CD2. Staining for CD30 was performed in 24 of 
27 cases. In 4 cases, CD30 expression was found in almost 100%, more than 50%, 
30%, and 15% of the neoplastic T cells, respectively, while in the other 20 cases 
no or few (< 10%) CD30+ neoplastic T cells were found. 
In 24 of the 27 SS cases, more than 50% of the neoplastic T cells in the skin 
expressed PD-1, in 22 cases even more than 75% (Figure 1 and Table 2). Six 
follow-up biopsy specimens of 3 of these 24 patients, obtained 24 to 48 months 
after diagnosis, also showed expression of PD-1 by more than 75% of the neoplastic 
T cells. PD-1 was expressed by small to large atypical T cells with cerebriform 
nuclei (Sézary cells) as well as by (CD30+) blast cells. In the other three cases, PD-1 
was expressed by approximately 25% in 1 case, less than 10% in another case, 
while in the third case the neoplastic T cells were completely negative for PD-1. 
In the patient with less than 10% PD-1+ neoplastic T cells in the skin infi ltrate, the 
lymph node biopsy specimen showed a diffuse population of PD-1+, CD3+, CD4+ 
neoplastic T cells. A diffuse infi ltration by PD-1+ tumor cells was also observed in 
the lymph node biopsy specimens from 3 other patients with SS. 
Serial skin sections showed that CXCL13 and BCL6 generally stained 25% to 
50% of the PD-1+ cells (Figure 1). In the 2 cases with less than 10% PD-1+ tumor 
cells, CXCL13 was expressed by 25% to 50% and BCL6 by approximately 25% of 
the neoplastic T cells. Staining for CD10 was performed in 25 cases, and results 
were negative in 21 cases. In the other 4 cases, all of them with more than 50% 
PD-1+ tumor cells, CD10 was expressed by 100% of the neoplastic T cells in 1 case 
and by 25% to 50% in the other 3.
Mycosis fungoides 
Immunostaining showed a CD4+CD8– T-cell phenotype in 36 patients, a CD4–
CD8+ T-cell phenotype in 9 patients and a CD4–CD8– T-cell phenotype in 15 of 
60 patients. Including the 15 CD4–CD8– cases, marker loss was observed in 35 of 
60 biopsy specimens (58%), including 16 of 30 patches or plaques (53%), 14 of 22 
tumors (64%), and 5 of 8 E-MF (63%). Expression of CD30 by more than 25% of 
the neoplastic T cells was observed in 11 biopsy specimens, including 5 plaques, 
























Expression of PD-1 by more than 50% of the neoplastic T cells was observed 
in 8 of 60 patients (13%), including 4 of 30 patches or plaques (13%), 3 of 22 
tumors (14%), and interestingly, only 1 of 8 biopsy specimens from E-MF (13%). PD-1 
expression was signifi cantly higher in the SS group compared with the total MF 
Figure 1. Histopathologic features of a representative patient with Sézary syndrome. (A) The 
hematoxylin-eosin staining of the lesion showed a superfi cial band-like dermal infi ltrate and epidermal 
Pautrier microabscesses with CD4+ (B) CD3+ (C) neoplastic T cells. These neoplastic T cells showed 
strong PD-1 positivity (D), and serial skin sections showed that BCL6 (E) and CXCL13 (F) was expressed 
by 25% to 50% of the PD-1+ cells. A-D, Original magnifi cation x100. E and F, Original magnifi cation 
























group (p < 0.001), as well as compared with the E-MF group (p < 0.001). The results 
of PD-1 staining in a second biopsy, obtained from either a preceding plaque or 
a subsequent tumor in 8 of 60 patients, were identical to those of the fi rst biopsy. 
The 8 PD-1+ cases included both patients with a CD4+CD8– phenotype (4 cases), 
a CD4–CD8+ phenotype (1 case) and a CD4–CD8– T-cell phenotype (3 cases). In 
these cases, PD-1 stained both atypical T cells with cerebriform nuclei and (CD30+) 
blast cells. In the 11 biopsy specimens containing more than 25% CD30+ tumor 
cells, PD-1 was expressed by 30% to more than 75% of the CD30+ blast cells in 3 
cases, while these cells were negative for PD-1 in the other 8 cases. In addition to 
the 8 cases with more than 50% PD-1+ tumor cells, in 1 case 25% to 50% and in 3 
cases 11% to 25% of the neoplastic T cells expressed PD-1 (Table 2). In the other 
48 cases, no or sometimes few (but always < 10%) neoplastic T cells expressed 
PD-1 (Figure 2), while in all biopsy specimens small numbers of reactive PD-1+ T 
cells were observed, serving as an internal control. Examination of serial sections 
showed that both CXCL13 and BCL6 generally stained 25% to 50% of the PD-1+ 
cells. CD10 was expressed by almost all neoplastic T cells in only 1 of 8 biopsy 
specimens with more than 50% PD-1+ tumor cells, and in none of the 10 biopsy 
specimens with 10% to 50% PD-1+ tumor cells.
 
Additional studies in E-MF
After this initial analysis additional skin and lymph node biopsy specimens were 
collected from 6 of 8 patients with E-MF. These biopsies were obtained from 
plaques 4 and 20 years before the development of erythroderma (cases 2 and 
3) (Table 1), from erythrodermatous skin during follow-up 12 to 60 months after 
diagnosis (cases 3, 6 and 8) (Table 1), and from diffusely involved lymph nodes (N3 
stage; cases 1, 5, 6, and 8) (Table 1). Four patients showed folliculotropic infi ltrates 
both in the fi rst biopsy specimens at the nonerythrodermatic stage and in the 
Table 2. Results of PD-1 expression in skin biopsy specimens of patients with SS and MF
PD-1+ neoplastic T cells, No. (%)
Type of lymphoma Cases, No. >50% 11%-50% <10%




















  6 (75%)
a Patients with SS (n=27) versus those with MF (n=60): p < 0.001
























follow-up biopsy specimens at the erythrodermatic stage. In the single patient who 
was PD-1+ (case 2) (Table 1), PD-1 was expressed by more than 75% of the neoplastic 
T cells both in the erythrodermatous skin and in the plaque biopsied 20 years 
before. In the 5 other patients, PD-1 was consistently negative, both in preceding 
plaques, follow-up biopsy specimens and involved lymph nodes (Table 1).
DISCUSSION
In the present study we observed a differential expression of PD-1 in skin biopsy 
specimens from patients with SS and MF. In 24 of 27 patients with SS (89%), PD-1 
was expressed by more than 50% of the malignant T cells, while in 1 of the 3 
remaining cases the neoplastic cells in the involved lymph node were PD-1+. In 
contrast, in only 8 of 60 patients with MF (13%), PD-1 was expressed by more than 
50% of the neoplastic cells. 
Figure 2. Histopathologic features of a representative patient with MF who was negative for 
programmed death-1 (PD-1). (A) The hematoxylin-eosin staining (original magnifi cation x100) of the 
lesion showed an epidermal and superfi cial dermal infi ltrate with CD4+ (B) CD3+ (C) neoplastic T cells. 
























The proportion of PD-1+ MF cases (13%) in our study contrasts with the results 
of 3  other studies.6;13;14 Wada et al.6 reported a percentage of more than 50% PD-1+ 
tumor cells in 6 of 15 patches or plaques (40%), 9 of 15 tumors in MF(60%), and in 8 
of 11 biopsy specimens from patients with SS (63%). In the study of Kantekure et al.13 
16 of 26 MF biopsy specimens (62%) contained more than 25% PD-1+ tumor cells, 
but if the cut-off point of 50% of the present study was used, only 7 of 26 biopsy 
specimens from patients with MF (26%) were PD-1+. Roncador et al.14 observed 
PD-1 expression in 5 of 9 MF cases (56%) but did not provide a cut-off point for 
PD-1 positivity. The results of the present study are consistent with those of a 
previous study of our group.12 In that study, which was focused on PD-1 expression 
in PCSM-TCL and/or pseudo-T-cell lymphomas, 21 cases of MF with a CD4+CD8– 
T-cell phenotype were included as a control group, and expression of PD-1 by 
more than 50% of the neoplastic T cells was found in only 2 of 21 cases. In the 
present study, we did not only include cases with a CD4+ T-cell phenotype, but —to 
cover the whole spectrum of MF— our database was actively searched for cases 
with a CD4–CD8+ and CD4–CD8– T-cell phenotype, cases with CD30 expression 
in a considerable proportion of tumor cells (since 1 of the 2 PD-1+ MF cases from 
our previous study strongly expressed CD30), as well as cases with E-MF. PD-1 
expression was found not only in cases with a CD4+CD8– T-cell phenotype, but also 
in cases with a CD4–CD8+ or CD4–CD8– T-cell phenotype, and both in CD30+ and 
CD30– cases. The expression of PD-1 by CD30+ blast cells in some cases of MF and 
SS is of interest, since the neoplastic CD30+ T cells in cutaneous anaplastic large-
cell lymphoma and lymphomatoid papulosis are consistently negative for PD-1.12
Remarkably, expression of PD-1 by more than 50% of the neoplastic T cells was 
observed in only 1 of the 8 patients with E-MF. In this patient, both erythroderma 
and the initial plaque-like lesion biopsied 20 years before were strongly positive 
for PD-1. In the other 7 patients, all skin and lymph node biopsy specimens were 
consistently negative for PD-1. It should be noted that, during follow-up, 4 patients 
in this group developed peripheral blood involvement, meeting the criteria 
normally used for the diagnosis of SS (B2 stage) (Table 1). There is controversy as 
to how such patients with MF developing peripheral blood involvement during 
follow-up should be designated. Some might prefer to simply use the term SS,17 
others like SS preceded by MF18 or secondary SS,19 but we designate such cases 
E-MF with blood involvement.
These observations are important for the ongoing discussion regarding the 
relationship between SS and MF. Often, SS is designated as a leukemic phase 
or leukemic variant of MF. Indeed, there are morphological (atypical cells with 
cerebriform nuclei) and phenotypical (CD3+CD4+CD8– T cells) similarities between 
both conditions, which resulted in the concept of CTCL.20 Moreover, patients 
with MF may sometimes present with erythroderma and/or develop peripheral 
























tumors as in MF. However, apart from the differences in clinical presentation and 
clinical course, there are also histological, phenotypical and genetic differences 
between both conditions. Histologically, the neoplastic T cells in early-stage MF 
preferentially colonize the basal layers of the epidermis, while the neoplastic T 
cells in SS show a preferential perivascular distribution with or without prominent 
epidermal infi ltration, refl ecting the leukemic nature of the disease.19;20 Consistently, 
involved lymph nodes in SS are generally overrun by a monotonous infi ltration of 
Sézary cells.21 In contrast, involved lymph nodes in MF show increased numbers 
of both atypical T cells with cerebriform nuclei and interdigitating reticulum cells, 
and in advanced stages blast cell transformation is much more pronounced than 
in SS lymph nodes.21 Phenotypically, SS consistently has a mature CD4+ T-cell 
phenotype. Also in MF, a CD4+ phenotype is most common, but patients may also 
present with a CD4–CD8+ or a CD4–CD8– T-cell phenotype.22 Moreover, both in 
the present study and previous studies on involved lymph nodes, loss of pan–T-
cell antigens (CD2, CD3, CD5) is frequently observed in skin lesions and involved 
lymph nodes in MF, in particular in patients with advanced disease.23 In contrast, 
the neoplastic T cells in skin and lymph nodes of patients with SS generally retain 
their mature CD4+ T-cell phenotype, even in patients with advanced disease.23 In 
the present study, loss of pan–T-cell antigens was observed in only 1 of 27 patients 
with SS. More recent phenotypical studies showed that the neoplastic T cells 
obtained from the peripheral blood of patients with SS have a central memory 
T-cell phenotype, while T cells isolated from MF skin lesions had skin resident 
effector memory T-cell phenotype.24;25 The authors suggested that SS and MF 
should be considered as separate lymphomas arising from distinct functional T-cell 
subsets.24;25 Also, recent genetic studies showing major oncogenetic differences 
between SS and tumor-stage MF suggested that these are distinct entities.26;27 
The almost consistent expression of PD-1 and CXCL13 in SS28 and the uncommon 
expression in MF also support the view that SS and MF should be considered as 
distinct entities. This would imply that in future trials these conditions should be 
considered separately.
The consistent expression of PD-1, CXCL13, and BCL6 by the neoplastic cells in 
SS is similar to that of TFH cells in the germinal centers of lymph nodes, and similar 
to the neoplastic T cells in AITL, now commonly designated as a tumor of TFH 
cells.1;3 This raises the question of whether the neoplastic cells in SS are derived from 
TFH cells and/or have the functional characteristics of these TFH cells. TFH cells 
are located in the germinal centers in lymph nodes providing essential support for 
B-cell maturation and plasma cell development. The chemokine CXCL13 selectively 
recruits CXCR5+ B cells into the follicle and is involved in the activation of B cells.10 
CXCL13 is expressed by the malignant T cells in lymph nodes in AITL and has been 
suggested to contribute to B-cell dysregulation.29 However, such a role seems 
























and also in our MF biopsy specimens no relationship between PD-1 expression 
and the number of admixed B cells or plasma cells was found (data not shown).
Two recent studies suggest another role for CXCL13 and PD-1 in SS. Picchio et 
al. found high expression of CXCL13 in skin lesions, lymph nodes and peripheral 
blood of patients with SS and noted that plasma levels of functional active 
CXCL13 increased signifi cantly during disease progression.28 Interestingly, while 
the neoplastic T cells in most patients with SS were positive for CXCL13 (13 of 
16 [81%] cases), in patients with MF only 4 of 14 cases (28%) expressed CXCL13, 
which nicely parallels our observations on PD-1 expression in these conditions. 
Picchio et al.28 proposed that CXCL13 acts in synergy with CCR7 agonists CCL21 
(present in both skin and lymph node of patients with SS) to promote the skin and 
lymph node homing of the Sézary cells that are known to have high expression 
CCR7.30 In another study, Samimi et al.5 found increased PD-1 expression in the 
circulating neoplastic T cells in patients with SS compared with patients with MF 
and healthy controls. They observed a strong decrease in PD-1 expression with 
improvement of disease. Moreover, an increase in interferon gamma production 
was found in cultures of PBMC from patients with SS if the PD-1/PD-L1 interaction 
was interfered by blocking anti–PD-1 antibodies. They suggested that the high 
PD-1 expression may contribute to immunosuppression in SS, but the mechanisms 
involved are as yet unknown. Given the high expression of PD-1 in Sézary cells, 
it is tempting to speculate that PD-1 on Sézary cells may serve as a potential 
target for immunotherapy. Interestingly, fully-human blocking antibodies for PD-1 
have recently been tested in a phase I clinical trial, showing promising results for 
different types of PD-L1+ solid tumors that are assumed to attenuate the PD-1+ 
tumor infi ltrating T lymphocytes.31 Although in case of SS the situation is different 
—SS is a T-cell tumor and the neoplastic cells are PD-1+ themselves— it may very 
well be that patients with SS may benefi t from anti–PD-1 immunotherapy as well.
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Background: Histologic differentiation between Sézary syndrome (SS) and 
erythrodermic infl ammatory dermatoses (EID) can be very diffi cult. Recent studies 
show that programmed death-1 (PD-1) is strongly expressed by the neoplastic cells 
in skin biopsies of SS, while similar studies in EID are lacking.
Objective: To determine whether the number and distribution of PD-1+ T cells could 
be used as an adjunct in the differentiation between SS and EID.
Methods: Expression of PD-1 and a panel of T-cell markers was investigated in 
skin biopsies from 30 patients with various types of EID (12 idiopathic, 10 atopic, 
6 psoriatic and 2 paraneoplastic) and 25 patients with SS.
Results: Expression of PD-1 by more than 50% of the infi ltrating T cells was observed 
in 23 of 25 SS cases (92%) and only in 4 of 30 EID cases (13%). PD-1 is expressed by 
neoplastic CD4+ T cells in SS, while in contrast, PD-1 was predominantly expressed 
by dermal and epidermal CD8+ T cells in EID. Expression of CD7 by ≤ 20% of the 
infi ltrating T cells was observed only in SS (13 of 24; 54%), and not in any of the 
30 cases of EID. 
Conclusions: While PD-1 is expressed by CD4+ neoplastic T cells in SS, our results 
suggest that PD-1 is expressed mainly by activated dermal and epidermal CD8+ T 
cells in EID. Expression of PD-1 by > 50% of CD4+ T cells and expression of CD7 by 
≤ 20% of the infi ltrating T cells strongly support a diagnosis of SS in skin biopsies 
of patients with erythroderma.
What is already known about this topic? 
• Histological differentiation between Sézary syndrome (SS) and erythrodermic 
infl ammatory dermatoses (EID) is often diffi cult. 
• Programmed death-1 (PD-1) is strongly expressed by the neoplastic cells in 
skin biopsies of SS suggesting diagnostic potential, but similar studies in EID 
are lacking.
What does this study add? 
• PD-1 is expressed not only by CD4+ neoplastic T cells in SS, but also by 
activated (epi)dermal CD8+ T cells in EID. 
• Expression of PD-1 by > 50% of CD4+ T cells and expression of CD7 by ≤ 20% 










































Programmed death-1 (PD-1; CD279) is expressed by activated T cells and upon 
binding to its ligands PD-L1 or PD-L2, a co-inhibitory signal is provided promoting 
apoptosis, anergy and functional exhaustion.1 PD-1 is constitutively expressed by 
CD4+ follicular helper T (TFH) cells and plays a role in germinal center formation 
and plasma-cell development.2 Recent studies show that the neoplastic cells in 
angioimmunoblastic T-cell lymphoma (AITL) express PD-1, CXCL13, BCL6 and 
CD10.3,4 Because of this phenotypical resemblance to TFH, AITL is now commonly 
considered as a tumor of TFH cells. We and others reported that the atypical 
medium-to-large CD4+ T cells in primary cutaneous CD4+ small/medium-sized 
pleomorphic T-cell lymphoma (PCSM-TCL) also express PD-1. As 25% to 75% of 
these PD-1-positive cells also express CXCL13 and BCL6, it has been suggested 
that this type of cutaneous T-cell lymphoma (CTCL) may also originate from TFH 
cells.5-7
In another study of our group, it was shown that PD-1 was —almost without 
exception— strongly expressed by more than 50% of the neoplastic T cells in 
Sézary syndrome (SS), but uncommonly (13%) by the tumor cells in skin lesions of 
mycosis fungoides (MF).8 In other reports, PD-1 expression by the neoplastic T cells 
was found in 50% to 60% of skin biopsy samples of patients with MF,3,9,10 however, 
in these studies different cut-off points for PD-1 positivity were applied.8 Based on 
our previous results it is therefore tempting to consider PD-1 expression by more 
than 50% of the T cells in a skin biopsy of a patient with erythroderma as supportive 
evidence for a diagnosis of SS. However, caution is warranted, since reports on 
PD-1 expression in skin biopsies of patients with an erythrodermic infl ammatory 
dermatosis (EID) are lacking. It is well known that histologic differentiation between 
SS and EID can be extremely diffi cult. In a recent study, blind evaluation of 
hematoxylin-eosin stained sections from skin biopsies of 18 patients with a CTCL, 
including 14 patients with SS and 29 patients with an EID, correct differentiation 
between CTCL and EID was made in approximately 50% of cases.11 
In the present study, the expression of PD-1 and other markers was investigated 
in skin biopsies of 30 patients with various types of EID, and compared with a group 
of 25 patients with SS described previously.8 In addition, the density and cellular 
composition of the dermal infi ltrates, the extent and phenotype of epidermotropic 
T cells and the presence of marker loss by the infi ltrating T cells were evaluated. 
The main goal was to investigate whether the number and distribution of PD-1+ T 









































PATIENTS AND METHODS 
Patients
Paraffi n-embedded skin biopsies from 30 patients with an EID were selected 
for this study. This group included 12 patients idiopathic erythroderma, 10 
patients with atopic erythroderma, 6 patients with erythrodermic psoriasis and 
2 patients with paraneoplastic erythroderma. In each patient the diagnosis 
was based on a combination of clinical and histological criteria, supplemented 
by immunophenotyping and clonality analysis of peripheral blood to exclude 
peripheral blood involvement by a CTCL. Review of clinical records revealed that 
none of the patients developed a lymphoma during follow-up. The 30 patients with 
an EID were compared with a group of 25 patients with SS from a previous study.8 
The diagnosis of SS was based on the criteria of the World Health Organization– 
European Organization of Research and Treatment of Cancer classifi cation (WHO-
EORTC) classifi cation of primary cutaneous lymphomas.12 The study complied with 
the Declaration of Helsinki and was performed in accordance with the Dutch Code 
and Leiden University Medical Center guidelines on leftover material.
Histology and Immunohistochemistry
Sections from all biopsies had routinely been stained with hematoxylin/eosin and 
with monoclonal antibodies against T-cell-associated antigens (CD2, CD3, CD4, 
CD5, CD7, CD8), B-cell-associated antigens (CD20 and/or CD79a), and CD68 and 
CD1a to differentiate between CD4+ T cells and CD4+ histiocytes and Langerhans 
cells/dendritic cells, respectively. For the purpose of this study, sections from 
all patients were stained for PD-1, BCL6 and CXCL13, as described previously.6,8 
Using a semiquantative analysis on serial sections, the percentages of CD3+ T 
cells expressing CD4, CD8, PD-1, BCL6 or CXCL13 were scored as < 10%, 11–25%, 
26–50% or > 50%, both in the epidermal and dermal compartments. These 
percentages were estimated independently by three observers (F.C., P.M.J., R.W.). 
In the few cases in which there was disagreement, sections were read jointly and 
consensus was reached. Loss of pan-T-cell antigens (CD2, CD3, CD5, CD7) was 
defi ned as expression by < 50% of CD3+ T cells.
RESULTS
Erythrodermic infl ammatory dermatoses
The EID generally showed sparse-to-moderately dense perivascular-to-band-like 
infi ltrates in the superfi cial dermis. Intraepidermal T cells were few or absent, and 









































to-extensive exocytosis was observed in only 4 of 30 cases (Table 1). Remarkably, 
in one case of paraneoplastic erythroderma, intraepidermal T cells were lined 
up along the basal epidermal layer (Figure 1). Pautrier microabscesses were not 
observed.
Figure 1. Skin biopsy of a patient with paraneoplastic erythroderma. (a) Haematoxylin-eosin 
staining of the lesional skin. (b–d) Serial sections from the same area stained for CD4 (b), CD8 (c) and 
programmed death-1 (PD-1) (d). Positive-stained cells can be recognized by the brown color. (e, f) 
Higher magnifi cation of the marked areas in (c) and (d), respectively, showing a remarkable lining up 
of the CD8+ and PD-1+ intraepidermal T cells along the basal membrane. Original magnifi cation: (a–d) 









































Table 1. Immunohistochemical results
Idiopathic
erythroderma
(n = 12), n (%)
Atopic
erythroderma
(n = 10), n (%)
Psoriatic
erythroderma
(n = 6), n (%)
Paraneoplastic
erythroderma
(n = 2), n (%)
Sézary
syndrome
(n = 25), n (%)
Exocytose 
No 2  (17) 1 (10) 0 0 6 (24)
Few 8 (66) 8 (80) 6 (100) 1 (50) 8 (32)
Moderate 1 (8) 1 (10) 0 1 (50) 0
Extensive 1 (8) 0 0 0 11 (44) *
Pautrier 0 0 0 0 10 (40)
Epidermal CD4/CD8 T-cell ratio
CD4 > CD8 2 (20) 0 0 0 14 (74)
CD4 = CD8 1 (10) 0 0 0 1 (5) †
CD4 < CD8 7 (70) 8 (100) 6 (100) 2 (100) 4 (21) †
Density dermal infi ltrate
Sparse 7 (58) 6 (60) 5 (83) 1 (50) 1 (4)
Moderate 4 (33) 4 (40) 1 (17) 1 (50) 19 (76)
Extensive 1 (8) 0 0 0 5 (20)
Dermal CD4/CD8 T-cell ratio
CD4 > CD8 10 (83) 3 (30) 2 (33) 0 25 (100)
CD4 = CD8 2 (17) 3 (30) 3 (50) 0 0
CD4 < CD8 0 4 (40) 1 (17) 2 (100) 0
Dermal CD8+ T cells
< 10% 3 (25) 0 0 0 11 (44)
10 – 25% 5 (41) 1 (10) 2 (33) 0 13 (52)
26 – 50% 4 (33) 5 (50) 3 (50) 0 1 (4)
> 50% 0 4 (40) 1 (17) 2 (100) 0
Median (range), % 20 (5–50) 50 (25–75) 30 (20–70) 67 (60–75) 12 (<5–30)
Dermal PD-1+ T cells
< 10% 7 (58) 0 1 (17) 1 (50) 1 (4)
10 – 25% 5 (41) 2 (20) 2 (33) 0 1 (4)
26 – 50% 0 5 (50) 3 (50) 0 0
> 50% 0 3 (30) 0 1 (50) 23 (92)
Median (range), % 5 (<5–20) 30 (20–75) 20 (10–30) 30 (5–60) 90 (<10–100)
Loss pan-T-cell marker (> 50%)
CD2, CD3, CD5 – – – – 1 (4)
CD7 3 (25) 1 (10) 0 0 16/24 (66)
PD-1, programmed death-1. *Presence of Pautrier microabscesses is considered as extensive irrespective of 









































The superfi cial dermal infi ltrates were composed mainly of small lymphocytes 
admixed with variable numbers of histiocytes. Eosinophils were observed in 9 of 
12 cases of idiopathic erythroderma, 6 of 10 cases of atopic erythroderma and 
one case of paraneoplastic erythroderma. In three cases of atopic erythroderma 
the dense superfi cial infi ltrates showed a predominance of slightly atypical small/
medium-sized pleomorphic T cells and scattered blast cells, and a diagnosis of 
(highly) suspected CTCL had initially been considered. One case of idiopathic 
erythroderma and one case of atopic erythroderma contained considerable 
numbers of CD30+ cells, while in all other cases scattered CD30+ blast cells were 
few or absent. Percentages of CD8+ T cells in the dermal infi ltrates varied between 
5% and 75% (median, 30%) of the dermal CD3+ T cells, and were most numerous in 
atopic erythroderma (Table 1). A predominance of CD8+ T cells (CD8/CD3 ratio > 
50%) was found in 4 of 10 cases of atopic erythroderma, one of 6 cases of psoriatic 
erythroderma and both cases of paraneoplastic erythroderma. Percentages < 25% 
were found in 11 of 30 cases, including eight cases of idiopathic erythroderma 
(Table 1). 
Figure 2. Skin biopsy of a patient with atopic erythroderma. (a) Haematoxylin-eosin staining of the 
lesion showing perivascular infi ltrates. (b–d) Serial sections from the same area stained for CD4 (b), 









































Although partial loss of CD7 by the dermal T cells was quite common, loss by 
> 50% was found in only 4 of 30 cases of EID. Loss of CD2, CD3 or CD5 was not 
observed. PD-1+ T cells varied between < 5% to 75% of the dermal CD3+ T cells 
and were most frequent in atopic erythroderma (Table 1). Percentages > 50% PD-1 
positivity — used as the cut-off point for positivity in CTCL, as described before8 
— were found in only 4 of 30 cases of EID: 3 cases of atopic erythroderma and 1 
case of paraneoplastic erythroderma. Examination of serial sections suggested that 
in 3 of these 4 cases PD-1 was predominantly expressed by CD8+ dermal T cells 
(Figure 2). BCL6 was expressed by < 5% up to 20% (median, 10%) of the dermal T 
cells, while CXCL13+ cells were few or absent. Epidermal PD-1+ T cells were few or 
absent. If present, they generally followed the staining pattern of intraepidermal 
CD8+ T cells (Figures 1 and 2). BCL6 expression by intraepidermal T cells could not 
be scored, because of the strong BCL6 expression by epidermal keratinocytes. 
Staining for CXCL13 was generally negative. 
Figure 3. Skin biopsy of a patient with Sézary syndrome. (a) Haematoxylin-eosin staining of the 
lesion showing dense perivascular infi ltrates in the papillary dermis. (b) T cells are visualized by CD3 
staining. (c) CD7 expression was expressed by < 20% of the neoplastic T cells, while (d) programmed 










































Skin biopsies from patients with SS, investigated for PD-1 expression in a 
previous study8, characteristically showed perivascular-to-band-like infi ltrates in 
the papillary dermis, which were generally more pronounced than observed in 
EID. More diffuse infi ltrates extending into the reticular dermis were observed in 
four cases. Epidermotropic neoplastic CD4+ T cells were contained mainly within 
Pautrier microabscesses (10 cases). Extensive epidermotropism outside Pautrier 
microabscesses was observed in only two cases, one of them in combination with 
Pautrier microabscesses. In the other 14 cases no (6 cases) or only few scattered 
intraepidermal T cells (8 cases) were observed. The dermal infi ltrates were composed 
predominantly of small-to-large atypical CD4+ T cells with hyperconvoluted nuclei 
(Sézary cells) and variable numbers of blast cells. In one of 25 cases, cellular atypia 
was minimal and a diagnosis of CTCL was at most suspected. In four cases 15% 
to 100% of the neoplastic T cells expressed CD30, while in the other 20 cases 
no or few (< 10%) CD30+ neoplastic T cells were found. Loss of CD7 by > 50% of 
the neoplastic T cells was found in 16 of 24 evaluable cases (66%), in 13 of these 
cases (54%) a loss of even more than 80% was observed (Figure 3). Loss of CD2 
was observed in one case, while in two other cases partial loss (< 50%) of either 
CD3 or CD2 was observed. In 23 of 25 SS cases (92%) more than 50% of the 
neoplastic CD4+ T cells in the skin expressed PD-1, in 21 cases even more than 
75%, including the case with only minimal atypia (Table 1). In the other two cases, 
PD-1 was expressed by approximately 25% in one case and less than 10% in the 
other. In the patient with < 10% PD-1+ neoplastic T cells in the skin infi ltrate, the 
lymph node biopsy showed a diffuse population of PD-1+CD3+CD4+ neoplastic T 
cells. Serial skin sections showed that CXCL13 and BCL6 generally stained 25–50% 
of the PD-1+ cells. 
DISCUSSION
The histologic diagnosis of SS in skin biopsies is one of the most challenging 
issues in dermatopathology. Recent studies of our group showed almost consistent 
expression of PD-1 by the neoplastic T cells of SS.8 In the present study the 
expression of PD-1 and other markers was investigated in skin biopsies from 30 
patients with various types of EID, and compared with 25 patients with SS from 
our recent study.8 The main goal of the present study was to determine whether 
the number and distribution of PD-1+ cells could be used as an adjunct in the 
differential diagnosis between EID and SS.
As described previously, PD-1 was strongly expressed by the large majority of 









































the epidermis.8 In skin biopsies of EID, percentages of PD-1+ T cells varied between 
< 5% to > 50% of the total number of infi ltrating dermal CD3+ T cells. They were 
most numerous in skin biopsies of patients with atopic erythroderma. Percentages 
> 50%, used in our previous study as a cut-off point for positivity in CTCL, were 
observed in only 4 of 30 cases (13%), including 3 cases of atopic erythroderma 
and one case with paraneoplastic erythroderma. Although double staining was not 
performed, examination of serial sections suggested that PD-1 was predominantly 
expressed by CD8+ T cells. In particular, the large majority of scattered PD-1+ 
intraepidermal lymphocytes were CD8 positive. BCL6 was expressed by < 5% up 
to 20% (median, 10%) of the dermal T cells, while CXCL13+ cells were few or absent. 
Expression of PD-1, but not of other TFH-cell markers BCL6 and CXCL13, suggest 
that these PD-1+ cells are activated T cells, and not TFH cells.
Other differences between skin biopsies of SS and EID concerned the density 
and cellular composition of the dermal infi ltrates, the extent and phenotype of 
epidermotropic T cells, and loss of pan-T-cell markers. Consistent with previous 
reports, skin biopsies of SS showed mainly perivascular infi ltrates, which were 
generally more pronounced and more monotonous than observed in EID 
biopsies.11,13,14 These infi ltrates were predominantly composed of small-to-large 
atypical CD4+ T cells with hyperconvoluted nuclei (Sézary cells) and variable 
numbers of blast cells. In three cases of atopic erythroderma the dermal infi ltrates 
also showed a predominance of slightly atypical small/medium-sized pleomorphic 
T cells and scattered blast cells and therefore a diagnosis of suspected CTCL had 
initially been considered. In addition, in one of them PD-1 was also expressed by 
> 50% of the dermal CD3+ T cells. However, percentages of CD8+ T cells varied 
between 40% and 60% in these cases, while percentages of admixed dermal 
CD8+ T cells in SS rarely exceeded 25%. Pautrier microabscesses containing CD4+ 
neoplastic T cells were observed in 10 of 25 cases of SS. Colonization of the 
basal layers of the epidermis, which is a characteristic feature of classical early-
stage MF, was observed in only two SS cases, and in one case of paraneoplastic 
erythroderma. However, in this latter case, the intraepidermal T cells expressed 
CD8 and not CD4 as in SS.
Loss of CD7 is a common feature in CTCL, but has also been reported in a 
variety of benign infl ammatory dermatoses, probably as a result of chronic T-cell 
activation.15;16 Unlike loss of other T-cell antigens, such as CD2, CD3 and CD5, loss 
of CD7 is therefore not considered as a useful criterion to differentiate between 
CTCL and infl ammatory skin diseases.15;16 In the present study, loss of CD7 by more 
than 50% of the infi ltrating T cells was observed in 16 of 24 cases of SS (66%), and 
only in 3 of 30 cases of EID (10%). In 13 of 24 cases of SS (54%) CD7 was expressed 
by ≤ 20% of the CD3+ T cells, while the percentages of CD7+ T cells in the 3 cases 









































therefore strongly supports a diagnosis of SS. Loss of other pan-T-cell markers 
(CD2, CD3, CD5) was not observed in EID, and only rarely in SS.
In conclusion, PD-1 expression by > 50% of skin-infi ltrating T cells in a patient 
with erythroderma is highly suggestive of a diagnosis of SS, but can also be 
observed —although uncommonly— in skin biopsies from patients with EID. In 
contrast to SS, in which PD-1 is expressed by CD4+ neoplastic T cells, our results 
suggest that in EID PD-1 is expressed mainly by activated dermal and epidermal 
CD8+ T cells. Partial loss of CD7 expression was common in both SS and EID, but 
expression of CD7 by ≤ 20% of the infi ltrating T cells was found only in SS. Our 
results suggest that expression of PD-1 by > 50% of CD4+ T cells and expression 
of CD7 by ≤ 20% of the infi ltrating T cells may be considered as valuable adjuncts 
in the differentiation between SS and EID.
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Background: The histopathologic differentiation between Sézary syndrome (SS) and 
erythrodermic dermatitis may be extremely diffi cult. In this immunohistochemical 
study, it was investigated if thymocyte selection-associated high mobility group 
box protein (TOX) and C-MYC can be used as additional diagnostic markers to 
differentiate between SS and erythrodermic dermatitis. 
Methods: Paraffi n-embedded skin biopsies from 15 patients with SS and 17 
patients with erythrodermic dermatitis were stained and scored for TOX or C-MYC 
expression.
Results: Strong nuclear staining for TOX in more than 50% of skin-infi ltrating T cells 
was observed in 13 of 15 SS cases (87%), whereas erythrodermic dermatitis cases 
showed weak nuclear staining in 11–50% (median, 25%) of the T cells; strong nuclear 
staining for TOX as found in SS was never observed in erythrodermic dermatitis. 
No signifi cant differences in C-MYC expression between SS and erythrodermic 
dermatitis were found. In most patients of both groups, percentages of C-MYC 
positive cells varied between less than 10–25% of skin-infi ltrating T cells.
Conclusions: Our results suggest that strong expression of TOX in more than 50% of 
skin-infi ltrating T cells in erythrodermic skin is a useful marker in the differentiation 
between SS and erythrodermic dermatitis, whereas staining for C-MYC does not 


























Sézary syndrome (SS) is a rare and aggressive type of cutaneous T-cell lymphoma 
(CTCL), characterized by a pruritic erythroderma and the presence of clonal 
neoplastic T cells (Sézary cells) in skin and peripheral blood.1 
The microscopic differentiation between SS and erythrodermic dermatitis 
may be extremely diffi cult.2,3 The histopathologic fi ndings of SS are similar to that 
of mycosis fungoïdes (MF), but more commonly the entity shows a monotonous 
band-like or perivascular infi ltrate in the papillary dermis, that is mainly composed 
of lymphocytes with atypical or cerebriform nuclei. Epidermotropism is present and 
Pautrier microabscesses may be found. However, in up to one third of SS cases, 
microscopic sections may show non-specifi c features of chronic dermatitis.4,5 
In a recent study, blind evaluation of hematoxylin and eosin-stained sections 
from skin biopsies of 18 patients with a CTCL, including 14 SS patients and 29 
patients with erythrodermic dermatitis, correct differentiation between CTCL and 
erythrodermic dermatitis was made in approximately 50% of the cases.3 These 
observations indicate that there is an urgent need for diagnostic biomarkers for SS.
In a recent study of our group both programmed death-1 (PD-1; CD279) and 
CD7 proved valuable immunophenotypic markers in the differentiation between 
SS and erythrodermic dermatitis.6 Expression of PD-1 by more than 50% of the 
skin-infi ltrating T cells was found in 23 of 25 SS cases (92%) and only in 4 of 30 
erythrodermic dermatitis cases (13%). In SS, PD-1 was expressed by the neoplastic 
CD4+ T cells, whereas in erythrodermic dermatitis PD-1 was predominantly 
expressed by dermal and epidermal CD8+ T cells. Loss of CD7 by more than 50% 
of the skin-infi ltrating T cells was found in 16 of 24 SS cases (66%) but also in 4 of 
30 erythrodermic dermatitis cases (13%). However, expression of CD7 by 20% or 
less of infi ltrating T cells was found only in SS (13 of 24 cases).
In this study, we used the same cohort of erythrodermic patients to investigate 
the differential diagnostic value of two other potentially useful biomarkers, namely 
thymocyte selection-associated high mobility group box protein (TOX) and C-MYC.
TOX belongs to a large family of chromatin-associated proteins. In T-cell 
development, TOX is highly expressed in the thymus during the transition of 
CD4+CD8+ precursors to CD4+ T cells but is normally not expressed by mature 
CD4+ T cells once they leave the thymus.7,8 
Recent studies have reported increased TOX expression by malignant CD4+ T 
cells in MF and SS skin biopsies, but not in benign infl ammatory dermatoses.9-12 In 
addition, Huang et al. showed that TOX mRNA expression is signifi cantly enhanced 
in primary CD4+CD7– cells from peripheral blood of SS patients, as compared to 
those cells from patients with benign infl ammatory dermatosis.13 The increase of 
TOX mRNA expression was correlated with increased risk of disease progression 

























development of CTCL.13 However, its biological effects on CTCL pathogenesis have 
not been explored. Studies focusing on TOX expression in skin of patients with 
extensive erythrodermic dermatitis have not been performed.
The rationale to consider C-MYC as a potential diagnostic marker results from 
previous studies showing a gain of 8q24 harboring the MYC gene in 41–75% of 
SS patients.14,15 Immunohistochemical studies for C-MYC expression in MF or 
SS are limited. Kanavaros et al. reported expression of C-MYC by 5–25% of the 
skin-infi ltrating lymphoid cells in cases of early stage MF and SS, whereas higher 
percentages (25–50%) were found in one-third of patients with advanced MF.16 In 
a recent study, 12 of 13 (92%) patients with erythrodermic MF/SS showed positive 
staining for C-MYC in at most 15% of the dermal lymphocytic infi ltrate cells.17 
In this study, we therefore investigated if TOX and C-MYC can be used as 
additional markers to differentiate between SS and erythrodermic dermatitis.
METHODS
Patients
Paraffi n-embedded skin biopsies from 15 patients with SS and 17 patients with 
erythrodermic dermatitis were selected for this study. The diagnosis of SS was based 
on the recent criteria of the World Health Organization – European Organization for 
Research and Treatment of Cancer classifi cation.1 The diagnosis of erythrodermic 
dermatitis in each patient was based on clinical and histopathological criteria, 
supplemented by immunophenotyping and clonality analysis of peripheral blood 
to exclude peripheral blood involvement by CTCL. The erythrodermic dermatitis 
group included four patients with atopic erythroderma, three patients with 
erythrodermic psoriasis, nine patients with idiopathic erythroderma and one 
patient with paraneoplastic erythroderma. Review of clinical records revealed that 
none of the patients developed a lymphoma after a median follow-up of 46 months 
(range, 7–332 months). The study complied with the Declaration of Helsinki and 
was performed in accordance with the Dutch Code and Leiden University Medical 
Center guidelines on leftover material.
Histopathology and immunohistochemistry
Sections from all skin biopsies had routinely been stained with hematoxylin-
eosin and with monoclonal antibodies against T cell-associated antigens (CD2, 
CD3, CD4, CD5, CD7 and CD8), B cell-associated antigens (CD20 and/or CD79a) 
and CD68 and CD1a to differentiate between CD4+ T cells and CD4+ histiocytes 
and Langerhans cells/dendritic cells, respectively. For the purpose of this study, 

























Immunohistochemical staining was performed on 4-μm sections using standard 
procedures. After antigen retrieval by heating for 10–12 minutes in 1.0 mmol/L 
ethylenediaminetetraacetic acid (pH 8.0) or 10 mmol/L citrate buffer (pH 6.0), tissue 
sections were incubated overnight with antibodies against TOX (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) and C-MYC (Abcam, Cambridge, United Kingdom). 
Sections were then incubated for 30 min with BrightVision Poly-horseradish 
peroxidase, and subsequently incubated with diaminobenzidin (DAB) solution 
(Sigma-Aldrich) for 10 minutes. Finally, all slides were counterstained with Mayer 
haematoxylin.
The percentages of T cells expressing TOX or C-MYC were scored, as less than 
10%, 11–25%, 26–50%, 51–75% and more than 75%. These percentages had been 
estimated independently by three observers (FC, PMJ, RW). In the few cases in 
which there were disagreement sections, they were viewed jointly by all authors 
and consensus was reached. 
RESULTS
Sézary syndrome
The results of the immunohistochemical stainings are summarized in Table 1. This 
table also contains the results of PD-1 staining and the presence or absence of 
antigen loss from our previous study.6 
Skin biopsies from patients with SS characteristically showed perivascular to 
band-like infi ltrates in the papillary dermis. More diffuse infi ltrates extending into 
the reticular dermis were observed in four cases. Epidermotropic neoplastic CD4+ T 
cells with (n = 5) or without (n = 5) Pautrier microabscesses were found in ten cases. 
The dermal infi ltrates were predominantly composed of small to large atypical 
CD4+ T cells with hyperconvoluted nuclei (Sézary cells) and variable numbers of 
blast cells. In 2 of 15 cases (nos. 6 and 15) the cellular atypia was minimal, and a 
diagnosis of CTCL was at most suspected. Percentages of admixed CD8+ T cells 
varied between less than 5% and almost 50%, but a percentage more than 30% 
was observed in only two cases (nos. 6 and 15). 
Strong nuclear staining for TOX was observed in more than 50% of the skin-
infi ltrating T cells in 13 of 15 (87%) with percentages more than 75% in ten of them 
(Table 1). Intraepidermal neoplastic T cells consistently showed strong nuclear 
staining for TOX (Figure 1). In two cases (nos. 6 and 15), weak nuclear staining in 
25–30% of the skin-infi ltrating T cells was found (Figure 2). C-MYC was expressed 
by less than 10% of the skin-infi ltrating T cells in 5 of 15 cases, by 11–25% in eight 
cases and in 26–50% in two cases. Strong nuclear C-MYC staining was particularly 
observed in large Sézary cells and blast cells (Figure 1). In addition, epidermal basal 

























Table 1. Summary of the immunohistochemical stainings
Case Diagnosis TOX (%) C-MYC (%) PD-1 (%) Antigen loss
1 SS ++++ + ++++ –
2 SS ++++ + ++++ CD7, CD2
3 SS ++++ + ++++ CD7
4 SS +++ – ++++ CD7
5 SS ++++ + ++++ CD7
6    SS * ++ (w) – +++ –
7 SS ++++ ++ ++++ CD7
8 SS +++ – +++ –
9 SS ++++ ++ ++++ CD7
10 SS ++++ + ++++ CD7
11 SS ++++ + + –
12 SS ++++ + +++ CD7, CD2
13 SS +++ – ++++ CD7
14 SS ++++ + ++++ CD7
15    SS * ++ (w) – +++ CD7
16    AE † + (w) – + –
17 AE + (w) – ++ –
18    AE † + (w) –    +++ ‡ –
19    AE † ++ (w) –    +++ ‡ CD7
20 PSOR + (w) + ++ –
21 PSOR + (w) – + –
22 PSOR + (w) – – –
23 IE + (w) + – –
24 IE ++ (w) – – –
25 IE ++ (w) + – –
26 IE + (w) + – –
27 IE ++ (w) – – –
28 IE + (w) + + –
29 IE + (w) + + CD7
30 IE + (w) + + –
31 IE + (w) – + –
32 PARA + (w) + + –
AE: atopic erythroderma; IE: idiopathic erythroderma; PARA: paraneoplastic erythroderma; PD-1, programmed 
death-1; PSOR: psoriatic erythroderma; SS: Sézary syndrome.
TOX, C-MYC and PD-1:  –, <10%; +, 11–25%; ++, 26–50%; +++, 51–75%; ++++, >75%
Antigen loss: loss of CD2, CD3, CD4, CD5 or CD7 expression by more than 50% of the (neoplastic) T cells; 
–: no loss.
* SS cases showing no or minimal cellular atypia
† Cases showing considerable numbers of  small to medium-sized atypical T cells


























Biopsy specimens of erythrodermic dermatitis generally showed a sparse to 
moderately dense perivascular to band-like infi ltrate in the superfi cial dermis, 
and the infi ltrate was generally much less pronounced than observed in SS. 
Intraepidermal T cells were few or absent, and in some cases could only be 
recognized in immunostained sections. The superfi cial dermal infi ltrate was mainly 
composed of small lymphocytes admixed with variable numbers of histiocytes, 
and in cases of atopic and idiopathic erythroderma with eosinophils. In three 
cases of atopic erythroderma (nos. 16, 18 and 19), the dermal infi ltrate showed 
a considerable number of slightly atypical small to medium-sized pleomorphic 
T cells and scattered blast cells, and a diagnosis of suspected CTCL had initially 
been made. Percentages of CD8+ T cells in the dermal infi ltrates varied between 
15% and 75% (median, 30%) of the dermal CD3+ T cells.
Figure 1. Histopathologic features of a representative Sézary syndrome patient with strong 
TOX expression. A) The haematoxylin-eosin staining shows an infi ltrate in the superfi cial dermis with 
epidermal Pautrier microabscesses. B) Expression of CD3. C) More than 50% of the skin-infi ltrating T 
cells show strong nuclear staining for TOX, particularly in large Sézary cells and blast cells. D) Less than 
25% of the skin-infi ltrating T cells expressed C-MYC. The insets in (C) and (D) show higher magnifi cations 

























Weak nuclear staining for TOX was observed in 11–25% of the infi ltrating T cells 
in 13 of 17 cases, and in 26–50% in four cases (Figure 3). Strong nuclear staining 
for TOX as found in SS was never observed in erythrodermic dermatitis. 
Nuclear staining for C-MYC was detected in 11–25% of both small and scattered 
larger T cells in 8 of 17 cases and by less than 10% in nine cases. In three cases, 
they were completely lacking (nos. 17, 18 and 19), whereas the epidermal basal 
cells still showed strong nuclear staining. 
DISCUSSION
In this study, strong nuclear staining for TOX by more than 50% of the skin-
infi ltrating T cells was found in 13 of 15 Sézary cases (87%), whereas all erythrodermic 
dermatitis cases showed weak nuclear staining of TOX varying between 11% and 
50% of the T cells. The two remaining SS cases (nos. 6 and 15) showed weak nuclear 
TOX expression at a similar level as seen in erythrodermic dermatitis patients. 
Interestingly, both cases showed minimal atypia and had high numbers of admixed 
CD8+ T cells. It should however be noted that in our previous study both cases 
had shown expression of PD-1 by more than 50% of the skin-infi ltrating T cells. 
Alternatively, in one SS patient with expression of PD-1 in only 10% of neoplastic T 
cells (no. 11), more than 75% of the neoplastic T cells showed strong nuclear TOX 
staining, suggesting that combining both markers may be diagnostically helpful. 
In a previous study, we observed that — in contrast to SS — PD-1 is uncommonly 
expressed by the neoplastic T cells in skin biopsies from erythrodermic MF. 
Expression of PD-1 by more than 50% of the neoplastic T cells was found in only 
one of eight cases.18 Examination of skin biopsies from seven of these cases showed 
Figure 2. Histopathologic features of a Sézary syndrome patient with weak TOX expression. A) 
The haematoxylin-eosin staining shows a perivascular to band-like infi ltrate in the papillary dermis. B) 

























strong nuclear staining for TOX by more than 50% of the malignant T cells in six of 
them (Willemze et al.; unpublished observations 2015). These results are similar to 
those of this study in SS and indicate that TOX is a useful biomarker to differentiate 
erythrodermic dermatitis from both SS and erythrodermic MF. 
Our results are consistent with recent studies showing strong nuclear staining 
for TOX by atypical CD4+ T cells, both in dermis and epidermis, in SS and MF skin 
biopsies compared with benign infl ammatory dermatoses and normal skin.9,10,12 In 
addition, previous studies have shown increased mRNA expression levels for TOX 
in both SS and MF as well.9-13 
The high expression of TOX in CTCL is as yet unexplained. In normal T-cell 
development mature CD4+ T cells do not express TOX after leaving the thymus. 
Whether the TOX expression found in SS and other types of CTCL may be because 
of an impaired regulated maturation status or to re-expression during the formation 
into memory T cell has yet to be determined.7 
Figure 3. Histopathologic features of a representative patient with erythrodermic psoriasis. A) 
The haematoxylin-eosin staining of the lesion shows acanthosis and and a dermal lymphocytic infi ltrate. 
B) Expression of CD3. C) Weak nuclear staining for TOX in a small proportion of the infi ltrating T cells. 


























No signifi cant differences in C-MYC expression between SS and erythrodermic 
dermatitis were found. In both groups about half of the cases showed C-MYC 
positivity in 11–25% of the skin-infi ltrating T cells. Higher percentages (25–50%) 
were found in only two cases of SS. Similarly, Kavanos et al. reported percentages 
of 11–25% in three of three (100%) SS cases.16 
Previous studies reported a gain of 8q24 harboring the MYC gene in 41–75% of 
SS patients.14,15 In a recent European multicenter study on 59 Sézary patients gain 
for MYC was found in 23 of 58 (40%) SS cases as well (Boonk et al. 2015, submitted 
manuscript). However, using the quantitative polymerase chain reaction technique, 
no differences in MYC gene expression levels were found between Sézary cells and 
CD4+ T cells from erythrodermic dermatitis patients. Three of the 15 SS cases (nos. 
2, 10 and 11) from this study had been included in the previous study and showed 
a gain for MYC. However, all of them showed C-MYC staining in only 11–25% of the 
skin-infi ltrating T cells, similar to the other SS cases. Why the gain for MYC does 
not lead to increased gene and protein expression is as yet unexplained.
In conclusion, strong expression of TOX, but not C-MYC, can be another useful 
adjunct in the differentiation between SS and erythrodermic dermatitis.
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Background: Numbers of programmed death-1 (PD-1) positive T cells have 
prognostic signifi cance in some types of nodal B-cell lymphomas, but data on 
PD-1 expression in cutaneous B-cell lymphoma (CBCL) are few. In this study we 
determined the expression and distribution of PD-1 on neoplastic B cells and 
reactive T cells in skin sections from primary CBCLs. 
Methods: By means of immunohistochemical staining, PD-1 expression was 
investigated in skin biopsies from 10 patients with primary cutaneous marginal zone 
lymphoma (PCMZL), 18 patients with primary cutaneous follicle center lymphoma 
(PCFCL) and 12 patients with primary cutaneous diffuse large B-cell lymphoma–leg 
type (PCLBCL–LT).
Results: Neoplastic B cells were negative for PD-1 in all cases, except for two cases 
of PCLBCL–LT. The frequency of PD-1+ T cells was signifi cantly higher in PCFCL than 
in PCMZL and PCLBCL–LT, accounting for 20%, 10% and 3% of the total number 
of infi ltrating cells, and 60%, 20% and 15% of the total number of CD3+ T cells, 
respectively.
Conclusions: PD-1 is rarely expressed by the neoplastic B cells in CBCL. High 
percentages of PD-1+ T cells, particularly if found outside germinal centers, support 
























Programmed death-1 (PD-1; CD279) belongs to the CD28/CTLA-4 receptor family 
and is expressed by CD4+ and CD8+ T cells after activation. Binding of PD-1 
to its ligands PD-L1 (CD274) or PD-L2 (CD273) inhibits T-cell functions, such as 
proliferation, cytokine production and cytotoxic activity.1,2 Follicular helper T (TFH) 
cells are a special subset of CD4+ T cells, which have a constitutive high expression 
of PD-1. TFH are important for the formation of germinal centers and regulate the 
differentiation of germinal-center B cells into plasma cells and memory B cells.3,4 
Interaction between PD-1 on the TFH cells and PD-L1 on the germinal-center B 
cells appears to enhance, rather than inhibit the germinal center reaction, however, 
the exact mechanism is not known.3,4
Several studies investigated PD-1 expression in nodal B-cell non-Hodgkin 
lymphomas (B-NHLs). Except for small lymphocytic lymphoma and rare cases 
of nodal follicular B-cell lymphoma and diffuse large B-cell lymphoma, PD-1 is 
generally not present on neoplastic cells in B-NHLs.5-7 However, PD-1 is detectable 
on variable amounts of tumor infi ltrating lymphocytes, in particular in follicular 
lymphoma.7-11 Several studies reported an association in these nodal follicular 
lymphomas between increased numbers of PD-1+ T cells and a signifi cantly improved 
survival, while in one study an association with a poorer outcome was found.7-10 
Information on the expression of PD-1 in primary cutaneous B-cell lymphomas 
(CBCLs) is limited. Fanoni et al. reported positive immunohistochemical staining 
for PD-1 in primary cutaneous follicle center lymphoma (PCFCL), but not in primary 
cutaneous marginal zone lymphoma (PCMZL) and primary cutaneous diffuse large 
B-cell lymphoma–leg type (PCLBCL–LT).12 However, the authors did not mention 
whether neoplastic B cells or reactive T cells were stained. In a very recent study, 
PD-1 was found to stain tumor-infi ltrating T cells, but no neoplastic B cells in these 
three types of CBCL.13
In this study, we investigated the expression of PD-1 in skin sections from 
primary CBCLs. The aim of this study was to fi nd out if PD-1 is expressed by the 
neoplastic B cells of these lymphomas. In addition, the number and distribution of 
PD-1+ T cells was investigated and correlated with clinical behavior.
METHODS 
Patients
Paraffi n-embedded skin biopsies from 10 patients with PCMZL, 18 patients with 
PCFCL and 12 patients with PCLBCL–LT were selected for this study. In addition, fi ve 
cases of cutaneous lymphoid hyperplasia (pseudo-B-cell lymphoma) were included 
as controls. All skin samples were collected from the archives of the Department of 























for Proper Secondary Use of Human Tissue”, which is approved by the Medical 
Ethics Committee of the LUMC. All CBCL cases had been reviewed by an expert 
panel of dermatologists and pathologists during one of the quarterly meetings 
of the Dutch Cutaneous Lymphoma group, and were classifi ed according to the 
criteria of the World Health Organization – European Organization of Research 
and Treatment of Cancer (WHO–EORTC) classifi cation for primary cutaneous 
lymphomas.14 All patients were adequately staged; physical examination, blood 
count, computed tomography scan and bone marrow biopsy were performed and 
showed no signs of extracutaneous disease manifestation at the time of diagnosis. 
The main clinical characteristics of these three groups of CBCL are presented in 
Table 1. 
Histology and Immunohistochemistry
Sections from all biopsies had routinely been stained with hematoxylin-eosin and 
immunostainings to detect B-cell–associated antigens (CD20, CD79a, cytoplasmic 
immunoglobulins), germinal center B-cell–associated antigens (BCL6 and CD10), 
T-cell–associated antigens (CD3, CD4, and CD8), BCL2 and IRF4/MUM-1.15 For the 
purpose of this study sections from all patients were stained for PD-1 and CXCL13. 
Staining procedures for PD-1 and CXCL13, using antibodies from R&D Systems 
Table 1. Clinical characteristics
PCMZL PCFCL PCDLBCL–LT
Number of cases 10 18 12
Male / Female 6/4 12/6 6/6
























































PCMZL, primary cutaneous marginal zone lymphoma; PCFCL, primary cutaneous follicle center lymphoma; 
PCLBCL–LT, primary cutaneous diffuse large B-cell lymphoma–leg type; A+, indicates alive with disease; A0, 























(Abingdon, UK), have previously been described.16,17 The percentages of CD3+ 
T-cells, PD-1+ cells and CXCL13+ cells were expressed as a percentage of the total 
number of skin-infi ltrating cells (both reactive and neoplastic). Using serial sections 
percentages of these cells were estimated independently by three observers (FC, 
PJ, RW) to the nearest 5% for the whole section. In the few cases in which there 
was disagreement, sections were read jointly and consensus was reached.
Statistical analysis
Statistical signifi cance was determined with one-way analysis of variance (ANOVA) 
and Student’s t-test using SPSS software, with p< 0.05 considered as signifi cant.
Figure 1. Histopathologic features of a representative primary cutaneous marginal zone lymphoma 
(PCMZL) patient. (A) Patient presenting with a tumor in the right popliteal area. (B) Hematoxylin-eosin 
staining of the lesion showing nodular to diffuse infi ltrates containing (C) CD79a+ neoplastic B cells and 
reactive follicles, and (D) high numbers of admixed T cells. (E) A small proportion of the T cells showed 
programmed death-1 (PD-1) positivity; these cells were typically found within reactive germinal centers. 
(F) A higher magnifi cation of the marked area in (E) showing a germinal center containing PD-1+ T cells. 
























PD-1 expression in PCMZL 
PCMZL showed nodular to diffuse infi ltrates containing variable numbers of 
marginal zone B cells, lymphoplasmacytoid cells and plasma cells and considerable 
numbers of admixed T cells (Figure 1). Reactive follicles were observed in 8 of 10 
cases. Plasma cells and/or lymphoplasmacytoid cells were characteristically found 
at the periphery of the infi ltrates or at the subepidermal border showing either 
kappa or lambda monotypic immunoglobulin light chain expression. The neoplastic 
B cells, including marginal zone B cells and plasma cells, were PD-1 negative in all 
cases (Table 2).
Admixed CD3+ T cells were numerous, in all cases comprising 50–75% (median, 
65%) of the total infi ltrate (Figure 1). The proportion of PD-1+ T cells varied between 
10% and 20% (median, 10%; mean, 13%) of the total infi ltrate, and made up 15–30% 
(median, 20%) of the CD3+ T cells (Table 2). Examination of serial sections showed 
that CXCL13 generally stained 25–50% of the PD-1+ cells. These PD-1+ T cells were 
particularly found within reactive germinal centers and less frequently outside, and 
were spatially not associated with plasma cells (Figure 1). A very similar pattern 
was found in fi ve cases of cutaneous pseudo-B-cell lymphoma. In these reactive 
lymphoid follicles PD-1+ T cells showed the same distribution as in normal reactive 
lymph nodes or tonsils, routinely included on the same glass slide as positive 
control. Clusters of four to six PD-1+ T cells rosetting around large B cells were 
regularly observed.
Table 2. Frequency of admixed CD3+ T cells and PD-1+ T cells
Reactive T lymphocytes







PCMZL 10 65% (50–75%) 10% (10-20%) 20% (15-30%)
PCFCL 18 35% (10–50%) 20% (5–40%) 60% (25–90%)
> follicular / follicular and diffuse 9 40% (15–50%) 25% (15–40%) 65% (30–90%)
> diffuse 9 25% (10–50%) 10% (5–30%) 50% (25–75%)
PCLBC–LT 12 13% (5–25%) 3% (1–15%) 15% (5–50%)
PCMZL, primary cutaneous marginal zone lymphoma; PCFCL, primary cutaneous follicle center lymphoma; 
PCLBCL–LT, primary cutaneous diffuse large B-cell lymphoma–leg type; PD-1, programmed death-1.
*proportion of CD3+ reactive T cells expressed as percentage of total number of infi ltrating cells.
† proportion of PD-1+ reactive T cells expressed as percentage of total number of infi ltrating cells.























Figure 2. Representative histopathologic features of a primary cutaneous follicle center lymphoma 
(PCFCL) patient with a mainly follicular growth pattern. (A) Hematoxylin-eosin staining of the lesion 
showing nodular infi ltrates containing neoplastic follicles with irregular mantles. (B) Neoplastic cells 
are CD79a positive. (C) BCL6 positive neoplastic germinal centers. (D and E) The neoplastic B cells are 
admixed with considerable numbers of small CD3+ T cells, of which (F and G) many were programmed 
death-1 (PD-1) positive. The insets in (E) and (G) are showing rosettes of CD3+ T cells and PD-1+ cells 
around large B cells, respectively. (A–D and F, original magnifi cation x25; E and G, original magnifi cation 























Figure 3. Representative histopathologic features of a primary cutaneous follicle center lymphoma 
(PCFCL) patient with a diffuse growth pattern. (A) Patient presenting with confl uent tumors on the 
back. (B) Hematoxylin-eosin staining of the lesion showing diffuse infi ltrates containing (C) CD79a+ 
neoplastic B cells. (D and E) Neoplastic B cells are admixed with considerable numbers of small CD3+ 
T cells, of which (F and G) many were programmed death-1 (PD-1) positive. The inset in (G) is showing 
the absence of PD-1 on neoplastic B cells (black arrowhead) and strong PD-1 expression on T cells 
(white arrowhead). (B–D and F, original magnifi cation x25; E and G, original magnifi cation x100; insert, 























PD-1 expression in PCFCL 
PCFCL showed nodular to diffuse infi ltrates containing medium-sized to large 
CD20+/CD79a+ cleaved cells (large centrocytes), variable numbers of centroblasts 
and considerable numbers of admixed small T cells (Figures 2 and 3). On the 
basis of routine histology and immunostains recognizing (remnants of) follicular 
dendritic cell networks (CD35 and CD21) these PCFCL showed either a purely 
follicular (n = 1), a follicular and diffuse (n = 8) or a diffuse growth pattern (n = 9). 
Characteristically, the neoplastic B cells expressed BCL6 (18/18 cases), but were 
negative for BCL2 (17/18 cases) and MUM-1 (18/18 cases), while CD10 was (partly) 
expressed in 6 of 16 cases investigated. Neoplastic B cells were PD-1 negative in 
all 18 cases (Table 2).
The proportion of admixed CD3+ T cells varied between 10% and 50% (median, 
35%) of the total infi ltrate, and was signifi cantly lower than in PCMZL (p < 0.01). 
PD-1+ cells made up 5–40% of the total infi ltrate (median, 20%) and were more 
frequent in cases with a (partly) follicular growth pattern than in cases with a diffuse 
growth pattern (Table 2). CXCL13 stained 25–50% of the PD-1+ cells. Examination 
of serial sections showed that PD-1 was expressed by more than 50% of the CD3+ 
T cells in 14 of 18 cases (Figures 2 and 3). The median percentage of 65% (range, 
25–90%) was signifi cantly higher than observed in PCMZL (p < 0.01) (Table 2). 
These PD-1+ T cells were particularly located within germinal centers or in areas 
with remnants of follicular dendritic cell networks. As in PCMZL, clusters of PD-1+ 
T cells rosetting around large B cells were regularly observed (Figure 2).
PD-1 expression in PCLBCL–LT 
PCLBCL–LT biopsies showed diffuse infi ltrates of centroblasts and immunoblasts, 
characteristically expressing BCL2 (11/11 cases) and MUM1 (10/12 cases), while 
BCL6 was expressed by 8 of 12 cases. Staining for CD10 was consistently negative. 
In 2 of 12 cases (17%) the neoplastic B cells showed weak PD-1 positivity (30% and 
60% of the tumor cells, respectively; Table 1; Figure 4).
There were few reactive CD3+ T cells (median, 13%; range, less than 5–25%) and 
signifi cantly less than in PCMZL (p < 0.01) and PCFCL (p = 0.01; Table 2; Figure 5). 
In 10 of 12 cases scattered PD-1+ cells made up less than 5% of the total infi ltrate, 
while CXCL13+ cells were observed only occasionally. Serial sections showed that 
PD-1 was expressed by 5% to 25% of CD3+ T cells in 11 of 12 cases. In one patient, 
a 53-year-old man presenting with tumor on the trunk, CD3+ T cells made up 25% 
of the total infi ltrate and 50% of these CD3+ T cells stained for PD-1. Compared 
to the nine PCFCL with a diffuse growth pattern, which also showed a diffuse 
population of large neoplastic B cells, these twelve PCLBCL–LT showed signifi cantly 
























In this study we investigated PD-1 expression in three types of primary CBCL: 
PCMZL, PCFCL and PCLBCL–LT. PD-1 was not expressed by the neoplastic B cells in 
these CBCL, except for two cases of PCLBCL–LT showing weak PD-1 staining in 30% 
and 60% of the neoplastic B cells, respectively. This observation is consistent with 
studies in nodal B-cell NHL, which showed that PD-1 is not or rarely expressed by 
the neoplastic B cells in follicular lymphomas and diffuse large B-cell lymphomas, 
neither in extranodal marginal zone lymphomas at non-cutaneous sites.5-7,18 In 
contrast to B-NHL, PD-1 is expressed by the neoplastic cells of several types of 
T-NHL, most notably angioimmunoblastic T-cell lymphoma (AITL), which is currently 
considered as the prototype of neoplasms derived from TFH cells.19,20 Regarding 
cutaneous T-cell lymphomas, PD-1, CXCL13 and BCL6, but –unlike AITL– not 
CD10, are consistently expressed by CD4+ small to medium-sized pleomorphic 
CTCL, but not or rarely by other types of primary cutaneous peripheral T-cell 
lymphoma, not otherwise specifi ed, and not by primary cutaneous CD30-positive 
lymphoproliferative disorders.16,21 In recent studies of our group, PD-1 was almost 
without exception strongly expressed by the neoplastic T cells in Sézary syndrome, 
but uncommonly by the tumor cells in skin lesions of mycosis fungoides.17
In this study we also looked for the number and distribution of reactive PD-1+ 
T cells in CBCL and found that PD-1+ T cells were signifi cantly more numerous 
in PCFCL than in PCMZL and PCLBCL–LT, which is consistent with the results of 
previous studies.12,13 In accordance, studies in nodal B-NHL showed signifi cantly 
higher numbers of PD-1+ lymphocytes in follicular lymphomas than in diffuse large 
B-cell lymphomas.7,8 In PCFCL these PD-1+ T cells were not only located within 
germinal centers, but also outside germinal centers. Examination of serial sections 
Figure 4. Histopathologic features of a primary cutaneous diffuse large B-cell lymphoma–leg type 
(PCLBCL–LT) patient with programmed death-1 (PD-1)+ neoplastic B cells. (A) Patient presenting 
with tumors on the dorsum of the right feet. (B) Hematoxylin-eosin staining of the lesion showing 
diffuse infi ltrates. (C) A considerable number of the neoplastic B cells in the lesion showed weak PD-1 
positivity (some positive cells are indicated by black arrowheads). (B, original magnifi cation x25; C, 























stained with follicular dendritic cell markers (CD21 and CD35) revealed that these 
areas with many PD-1+ T cells outside germinal centers still contained remnants of 
follicular dendritic cell networks, that were easily overlooked in routine hematoxilin-
eosin stainings. A very similar distribution has been described in nodal follicular 
lymphomas.7-11 In contrast, in PCMZL as well as the pseudo-B-cell lymphomas 
included as controls, PD-1+ T cells were preferentially localized within the germinal 
centers of reactive lymphoid follicles, and rarely present outside these follicles, 
which is in line with previous studies.12,13 The presence of many PD-1+ cells outside 
germinal centers may therefore be considered as an adjunct to differentiate PCFCL 
from pseudo B-cell lymphomas. Both in PCFCL and in PCMZL clusters of PD-1+ T 
cells, part of which were also CXCL13+, formed rosettes around large B cells, similar 
to TFH cells in reactive lymph nodes, as also reported in previous studies.12,13
Several independent studies indicate that higher frequencies of intratumoral 
PD-1+ lymphocytes are associated with improved overall survival in nodal follicular 
Figure 5. Histopathologic features of a primary cutaneous diffuse large B-cell lymphoma–leg 
type (PCLBCL–LT) patient. (A) Patient presenting with tumors on the medial side of the right ankle. 
(B) Hematoxylin-eosin staining of the lesion showing diffuse infi ltrates of large neoplastic B cells, (C) 
which are CD79a positive. (D) The infi ltrates contain few admixed reactive CD3+ T cells, of which (E) a 
small proportion showed programmed death-1 positivity. (B and C, original magnifi cation x25; D and 























lymphomas, although in one study a relationship with poorer outcome was 
reported.7-10 In addition, the PD-1+ T cell abundance correlates with histological 
grade, as grade III lesions tend to contain fewer PD-1+ cells than grade I and II 
follicular lymphomas. In line with this, we found that PCFCL with a follicular or a 
follicular and diffuse growth pattern contained higher frequencies of PD-1+ T cells 
than PCFCL with a diffuse growth pattern. In contrast, in the study of Mitteldorf et 
al. no relation between PD-1+ cells and growth pattern was found, which may relate 
to the small patient groups studied.13 However, PD-1 expression has no prognostic 
signifi cance in this group, as PCFCL has an excellent prognosis, irrespective of the 
growth pattern and the proportion of admixed (PD-1+) T cells.
For many years there has been discussion about the distinction between PCFCL 
with a diffuse growth pattern and PCLBCL–LT. In the WHO 2001 classifi cation both 
were still classifi ed as diffuse large B-cell lymphoma. However, studies in the last 
decade have fi rmly established that these represent distinct entities with a different 
clinical presentation, clinical behavior and prognosis, which are therefore classifi ed 
separately in recent consensus classifi cations.14,22 In this study PCFCL with a diffuse 
growth pattern contained signifi cantly more admixed PD-1+ T cells than PCLBCL–LT 
(50% versus 15%, respectively), suggesting that staining for PD-1 may serve as an 
adjunct diagnostic tool in diffi cult cases. 
In conclusion, our results show that PD-1 is rarely expressed by the neoplastic 
B cells in CBCL. Moreover, apart from germinal centers of reactive lymphoid 
follicles in PCMZL, high numbers of PD-1+ T cells are particularly found in PCFCL. 
In particular, the presence of many PD-1+ T cells outside germinal centers may 
support a diagnosis of PCFCL.
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The studies presented in this thesis are focused on the expression of the molecule 
programmed death-1 (PD-1) in cutaneous lymphomas. The main goal was to 
determine the presence and distribution pattern of this molecule in different types 
of primary cutaneous T-cell lymphomas (CTCL) and cutaneous B-cell lymphomas 
(CBCL) in order to fi nd out if PD-1 might be a useful biomarker to improve diagnosis, 
and possibly, to enable better classifi cation of provisionally classifi ed cutaneous 
lymphoma entities. In one chapter two additional markers were investigated, 
namely thymocyte selection-associated high mobility group box protein (TOX) 
and C-MYC. In this fi nal chapter, the results described in this thesis are summarized 
and compared with the data described in the literature and conclusions are drawn. 
PD-1 EXPRESSION AS DIAGNOSTIC MARKER FOR PRIMARY 
CUTANEOUS CD4+ SMALL/MEDIUM-SIZED PLEOMORPHIC 
T-CELL LYMPHOMA AND CUTANEOUS PSEUDO-T-CELL 
LYMPHOMA
In recent cutaneous lymphoma classifi cations [World Health Organization (WHO)-
European Organization for Research and Treatment of Cancer 2005; WHO 2008], 
primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma (PCSM-
TCL) is a cutaneous T-cell lymphoma (CTCL) that has been included as a provisional 
entity.1;2 Histologically, these lymphomas show nodular-to-diffuse infi ltrates with a 
predominance of CD3+, CD4+, CD8–, CD30– small to medium-sized pleomorphic 
T cells and a small proportion (<30%) of large CD4+ pleomorphic T cells. In most 
cases there is a considerable admixture with small reactive CD8+ T cells and CD20+ 
B cells, including some blast cells, histiocytes, and in some cases plasma cells and 
eosinophils. Clinically, these PCSM-TCL characteristically present with a solitary 
plaque or tumor that is generally localized on the face or the upper trunk, and 
uncommonly with multiple papules, plaques, or tumors.1;3;4 In particular, patients 
presenting with a solitary skin lesion have an excellent prognosis.5 The clinical, 
histological and immunophenotypical features of these PCSM-TCL are strikingly 
similar to those described previously in so-called pseudo-T cell lymphomas.6;7 
Demonstration of a T-cell clone and loss of pan-T-cell antigens are often used as 
diagnostic criteria for PCSM-TCL. However, using the Biomed-2 protocol, clonal 
TCR gene rearrangements are now found in most cases classifi ed as pseudo-T-cell 
lymphoma and loss of pan-T-cell antigens is not observed in PCSM-TCL presenting 
with a solitary lesion (Chapter 2). Therefore, the relationship between PCSM-TCL 
and pseudo-T-cell lymphomas is still a matter of debate. More important, these 

















other types of CTCL, in particular cutaneous peripheral T-cell lymphoma, not 
otherwise specifi ed (PTCL–NOS) and tumor stage mycosis fungoides (MF).
In 2009, Rodriguez-Pinilla et al. reported that the large atypical CD4+ T cells 
in PCSM-TCL express PD-1, BCL6, and CXCL13.Ref 8 In Chapter 2 we investigated 
expression of PD-1 and other TFH markers in skin biopsies of 26 cases classifi ed 
as either PCSM-TCL or pseudo-T-cell lymphoma and skin biopsies obtained from 
patients with MF and a cutaneous PTCL–NOS. The primary goal of this study 
was to determine whether PD-1 could serve as a useful marker to differentiate 
between PCSM-TCL and these other types of CTCL. In all 26 PCSM-TCL/pseudo-
T-cell lymphoma cases the medium-sized to large atypical T cells consistently 
expressed PD-1, which is in agreement with observations of more recent studies.9;10 
In addition, serial sections showed that CXCL13 generally stained 50–75% of the 
PD-1+ cells, and BCL6 25–50% of the PD-1+ cells, suggesting that these tumor cells 
might have been originated from TFH cells. In contrast, PD-1 expression was found 
in only 2 of 16 PTCL–NOS and in only 2 of 21 cases of MF. Although not a specifi c 
marker, the presence of scattered or small clusters of medium-sized atypical CD4+ 
T cells expressing PD-1 and many admixed small reactive CD8+ T cells, CD20+ B 
cells and histiocytes, strongly suggests a diagnosis of PCSM-TCL/pseudo-T-cell 
lymphoma. This characteristic pattern was found in both cases classifi ed initially 
as pseudo-T-cell lymphoma and cases classifi ed as PCSM-TCL. Therefore, we 
and others4 feel that there is no reason to classify PCSM-TCL and pseudo-T-cell 
lymphoma separately. There is increasing doubt if such cases should be considered 
as a genuine malignant lymphoma and, small- to medium-sized pleomorphic T-cell 
nodules of undetermined signifi cance and cutaneous CD4+ small-medium T-cell 
lymphoproliferation have been suggested as unifying terms for this condition 
(Beltraminelli et al.,4 and Chapter 2).
As all patients had an uneventful follow-up and that a skin relapse was only 
observed in a few cases, we suggest these cases should not be treated aggressively 
and no staging procedures should be performed. PCSM-TCL cases that do not 
meet the criteria described above are rare and should be fully staged. PCSM-TCL 
cases with rapidly growing multiple bulky tumors, a low percentage of admixed 
CD8+ T cells, and/or a high proliferative fraction, have been described to be at 
risk to develop progressive disease,5 but this study awaits further confi rmation.
Recently, Battisella and colleagues described fi ve patients with a CTCL, who 
presented with papules, nodules and/or infi ltrated plaques not preceded by chronic 
patches or plaques, excluding MF.11 Except for one patient with a solitary infi ltrated 
plaque, who responded well to radiotherapy, the other cases were relatively 
resistant to current therapies for CTCL. Histologically, these cases showed either 
a non-epidermotropic subepidermal band-like or a diffuse dense dermal lymphoid 
infi ltrate, containing about 50% CD3+ T cells and 50% CD20+ B cells. The infi ltrates 

















markers PD-1, BCL6, CXCL-13, CD10 or ICOS. Therefore, the authors suggested the 
term primary cutaneous TFH lymphomas for their cases. However, the relationship 
between these TFH-expressing CTCL and PCSM-TCL is at present unclear.
DIFFERENTIAL EXPRESSION OF PD-1 BY NEOPLASTIC 
CELLS IN SS AND MF 
In our initial study described in Chapter 2, PD-1 expression was found in only 
a small proportion of MF cases (2 out of 21 cases), which contrasted with the 
results of earlier studies.12-14 Moreover, our results in MF also contrast with the high 
expression of PD-1 reported in skin and peripheral blood of patients with SS.13;15 
This prompted us to investigate PD-1 expression in a large number of skin biopsies 
obtained from patients with SS and patients with MF, including cases with patch/
plaque, tumor and erythrodermic stage of diseases and cases with a CD4+CD8–, 
CD4–CD8+ and CD4–CD8– T-cell phenotype.
The results presented in Chapter 3 showed that PD-1 was expressed by more 
than 50% of the neoplastic T cells in the skin of the majority (89%) of patients with 
SS. The association of PD-1 with Sézary cells is very strong. Even if a cut-off level 
of 75% was applied, still 81% of the SS patients were PD-1 positive. In line with 
our observation, Wada and colleagues found PD-1 expression by Sézary cells in 
73% of skin biopsies of SS patients.13 In addition, Samimi and colleagues found 
increased PD-1 expression in the circulating neoplastic T cells in SS, but not in CD4+ 
peripheral blood T cells from patients with MF or healthy controls.15
Our data revealed that 25% to 50% of the PD-1+ neoplastic cells in SS co-
expressed CXCL13 and BCL6, so it may be questioned whether Sézary cells originate 
from TFH cells and/or have functional characteristics of TFH cells. Picchio et al.16 
found high expression of CXCL13 in skin lesions, lymph nodes, and peripheral 
blood of most patients with SS (over 80%), but only in a minority of patients with 
MF, which nicely parallels our observations. A derivation of Sézary cells from TFH 
cells seems unlikely, as the presence of B cells is uncommon in SS skin specimens 
and no relationship between PD-1 expression and the number of admixed B cells 
or plasma cells was found. Apparently, the simultaneous expression of TFH-cell 
markers PD-1, CXCL13, and BCL6 by a particular T cell does not necessarily mean 
that this cell is a TFH cell.
Consistent with results in chapter 2, the results in Chapter 3 show that PD-1 
expression by >50% of the neoplastic T cells was found in a minority (only 13%) 
of the MF cases. We did not observe differences in PD-1 expression between the 
patch/plaque, tumor and erythrodermic cases. In addition, no differences between 

















results confl ict with other studies on PD-1 expression in MF, showing variable 
(27–100%) PD-1 expression by the neoplastic T cells in MF specimens.10;12-14;17 
Despite six studies have been published on expression of PD-1 in MF (Table 1), 
no consensus is reached on this topic. The diversity of these observations may be 
explained by differences in cut-off levels of PD-1 positivity, antibodies and staining 
protocols (Table 1). Interestingly, 1 out of 8 E-MF cases showed PD-1 expression 
compared to 24 out of 27 cases of SS, which contributes to the debate on the 
relationship between both conditions.
RELATIONSHIP BETWEEN MF AND SS
The relationship between SS and MF is still a matter of debate as extensively 
discussed in Chapter 3. On the one hand, there is a general belief that SS is a 
leukemic phase or leukemic variant of MF because of the morphological atypical 
cells with cerebriform nuclei) and phenotypical (CD3+CD4+CD8– T cells) similarities 
between both conditions, which resulted in the concept of CTCL.18 In addition, 
patients with MF may sometimes present with erythroderma and/or develop 
peripheral blood involvement during follow-up, while rare pa tients with SS 
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may develop skin tumors as in MF. On the other hand, SS and MF show obvious 
differences in clinical presentation and course, there are histologic, phenotypic, 
and genetic differences between both conditions.19-26 The list of differences 
between SS and MF is still growing (summarized in Table 2) and multiple authors 
have suggested that SS and MF should be considered as distinct entities arising 
from different functional T-cell subsets. The almost consistent expression of PD-1 
and CXCL13 in SS (Chapter 3 and Picchio et al.16) and the uncommon expression 
of these markers in MF provide additional support for the view that SS and MF 
should be considered as distinct lymphomas.
Table 2. Differences between Sézary syndrome and mycosis fungoides
Feature Sézary syndrome Mycosis fungoides
clinical presentation erythroderma patches, plaques, tumor 
skin histology mainly perivascular epidermotropic
(basal layer) 
blood involvement by defi nition rare
lymph node histology monotonous Sézary cells dermatopathic 
lymphadenopathy + blast cell
CD4/CD8 phenotype consistently CD4+CD8– 
T-cell phenotype
may also present with CD4–CD8+ 
or CD4–CD8– phenotype
cell of origin central memory T cell effector memory T cell 
loss pan T cell markers
CD2, CD3, CD5
rare (even in patients with
advanced disease)
< 5% of patients
frequent (in particular in
advanced stage of disease)
> 50% of patients
PD-1 expression
(cut-off > 50% positivity)
> 90% of patients < 15% of patients 
DIFFERENTIAL DIAGNOSIS BETWEEN SÉZARY SYNDROME 
AND ERYTHRODERMIC INFLAMMATORY DERMATOSES
Clinical and histological differentiation between SS and erythrodermic infl ammatory 
dermatoses (EID) is one of the most challenging issues in dermatopathology. We 
found (Chapter 3) that PD-1 is expressed by Sézary cells in the vast majority of SS, 
representing the prototype of erythrodermic CTCL. We wondered whether PD-1 
would be a biomarker to distinguish SS from EID histologically. In contrast to the 
almost consistent expression of PD-1 in SS (92% of cases), our immunohistochemical 

















expressed by more than 50% infi ltrating dermal CD3+ T cells in only 4 out of 30 
cases (13%) While in SS PD-1 is mainly present by CD4+ neoplastic T cells, in EID 
PD-1 is predominantly expressed by CD8+ reactive dermal and epidermal T cells 
(Table 3). Although partial loss of CD7 expression can commonly be observed in 
both SS and EID, expression of CD7 by ≤ 20% of the infi ltrating T cells was only 
found in SS. Our results suggest that expression of PD-1 by more than 50% of 
CD4+ T cells and expression of CD7 by less than 20% of the skin-infi ltrating T cells 
may be considered as valuable adjuncts in the differentiation between SS and EID. 
Using the same cohort as in Chapter 4, in Chapter 5 we investigated the 
diagnostic signifi cance of two other markers TOX and C-MYC. Increased TOX 
expression by malignant CD4+ T cells has been found in MF and SS, but information 
on TOX expression in EID is lacking. In addition, C-MYC positivity has been 
demonstrated in a considerable number of infi ltrating lymphoid cells in MF and 
SS, while there is no information on C-MYC expression in EID.27-31 We demonstrated 
that TOX was strongly expressed by more than 50% of the neoplastic T cells in 13 
of 15 SS patients (87%), while all EID cases showed weak nuclear staining (Table 
3), showing TOX positivity between 11% and 50% of the T cells. Our results are 
consistent with recent studies also showing strong nuclear staining for TOX by 
atypical CD4+ T cells in skin28;31 and blood30 of SS patients compared to benign 
infl ammatory dermatoses and healthy controls. No signifi cant difference in C-MYC 
expression between SS and EID was found. In both groups C-MYC was expressed 
by 11-25% of the skin-infi ltrating T cells in about half of the cases. Kanavaros et 
Table 3. Differences between Sézary syndrome and benign erythroderma
Feature Sézary syndrome Benign erythroderma
Blood involvement 
• T cell clonality






Infi ltrate density moderate to extensive sparse to moderate
Epidermal T cells CD4+ T cells mainly CD8+ T cells
Dermal T cells CD4 >> CD8 CD4 ≥ CD8 or CD4 < CD8
Epidermal PD-1+ T cells only CD4 CD8 >> CD4
Dermal PD-1+ T cells
(cut-off > 50% positivity)
> 90% < 15%
TOX expression
(cut-off > 50% positivity)
> 85% < 5%
 Loss of CD7 expression


















al. and Goswami et al. reported similar percentages of C-MYC positivity in SS 
patients.32;33 Strong expression of TOX, but not C-MYC, can be another useful 
adjunct in the differentiation between SS and EID.
In conclusion, in order to make a proper distinction between SS and EID the 
a combination of the following criteria seems to be relevant (Table 3): presence 
of clonality of the T cells in blood/skin, the CD4/CD8 ratio of infi ltrating T cells in 
dermis and epidermis and in blood, the degree of epidermotropism, positivity of 
PD-1 and/or TOX by skin-infi ltrating T cells and presence of loss of CD7 expression.
PD-1 EXPRESSION IN CUTANEOUS B-CELL LYMPHOMAS
Several studies investigated PD-1 expression in nodal B-cell non-Hodgkin 
lymphomas (B-NHLs). Except for small lymphocytic lymphoma and rare cases 
of nodal follicular B-cell lymphoma and diffuse large B-cell lymphoma, PD-1 
is generally not present on neoplastic cells in B-NHLs.12;34;35 However, PD-1 is 
detectable on variable amounts of tumor infi ltrating lymphocytes, in particular 
in follicular lymphoma.35-39 In most studies increased numbers of PD-1+ T cells 
in these nodal follicular lymphomas are associated with a signifi cantly improved 
survival.35-38 As described in Chapter 6, we studied PD-1 expression in primary 
cutaneous B-cell lymphomas and found that this marker was absent on neoplastic 
B cells, but was present on variable amounts of reactive T cells. PD-1+ T cells 
were signifi cantly more numerous in primary cutaneous follicle center lymphoma 
(PCFCL) than in primary cutaneous marginal zone lymphoma (PCMZL) and primary 
cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL–LT). In both PCFCL 
and PCMZL, as well as in pseudo B-cell lymphomas, clusters of PD-1+ T cells, part 
of which were also CXCL13+, formed rosettes around large B cells, similar to TFH 
cells in reactive lymph nodes. We also showed that in PCFCL these PD-1+ T cells 
were not only located within germinal centers, but also outside germinal centers. 
These results were consistent with recent studies in CBCL.40;41
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
The results of the studies presented in this thesis demonstrated that PD-1 can serve 
as a useful tool in the diagnosis of CTCL in particular in PCSM-TCL/pseudo T-cell 
lymphomas and SS. However, it should be recognized that PD-1 is not specifi c 
marker, as the neoplastic T cells in some cases of CTCL (such as MF and PTCL–NOS) 

















PD-1. The presence of scattered or clusters of PD-1 on T cells in combination 
with many admixed CD8+ T cells, B cells, macrophages is highly suggestive of 
PCSM-TCL/ pseudo T-cell lymphomas and facilitates differentiation from other 
types of CTCL, such as tumor stage MF or PTCL–NOS. PD-1 and TOX are strongly 
expressed in SS (90%) and are useful adjuncts to differentiate SS from benign 
erythroderma.
Apart from its diagnostic signifi cance, PD-1 and PD-L1 expression in CTCL 
might also have therapeutic potential. The PD-1/PD-L1 pathway has emerged as 
an important mechanism by which tumors escape from the antitumor immune 
response. PD-1 is expressed by tumor-infi ltrating lymphocytes in many different 
types of tumors,42 while high PD-L1 expression has been reported in many 
human cancers.43 PD-L1 on the tumors binds to PD-1 on the tumor-infi ltrating T 
lymphocytes causing reduction of the effector function and killing capacity of these 
T cells and consequently facilitating immune evasion of the tumors.44 Ligation of 
PD-1 by PD-L1 can be obstructed with blocking monoclonal antibodies directed 
either to PD-1 or to PD-L1 thereby restoring the antitumor immunity. Recent clinical 
trials with antibodies targeting the PD-1/PD-L1 pathway in patients with cancer 
demonstrated promising antitumor responses.45;46 It was demonstrated that PD-1/
PD-L1 blockade is most effective in tumors with high PD-L1 expression,47;48 and it 
is proposed that tumor-associated PD-L1 expression can be used as biomarker for 
selecting patients who will have the best survival benefi t upon PD-1/PD-L1-pathway 
inhibitor therapy.
Considering the importance of the PD-1/PD-L1 pathway, the question arises 
whether this pathway can also serve as a potential target in patients with SS and 
MF. Kantekure et al. showed strong expression of PD-L1 by neoplastic large 
transformed T cells in MF.14 Whether the neoplastic T cells in SS — in addition to 
PD-1 — also express PD-L1 is at present unknown. Clinical trials investigating the 
effi cacy of an anti-PD-1 monoclonal antibody in patients with relapsed or refractory 
MF and SS have just started.
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Cutane lymfomen, oftewel huidlymfomen, zijn non-Hodgkin lymfomen die 
primair in de huid beginnen. Op het moment dat zij ontdekt worden, zijn er geen 
aanwijzingen dat het lymfoom elders in het lichaam voorkomt. Het is van groot 
belang om primaire cutane lymfomen te onderscheiden van lymfomen die in 
lymfeklieren zijn ontstaan en zich secundair manifesteren in de huid, omdat er 
tussen beide groepen grote verschillen bestaan in klinisch gedrag, prognose, 
therapie en reactie op behandeling. Cutane lymfomen zijn relatief zeldzaam. De 
geschatte jaarincidentie is 1:100.000 wat neer komt op circa 170 nieuwe patiënten 
per jaar in Nederland. Er bestaan diverse typen cutane lymfomen met een 
behoorlijk uiteenlopende relatieve frequentie (variërend van < 1% tot 45%) en 
ziektegerelateerde 5-jaarsoverleving (variërend van 0% tot 100%).
In de praktijk blijkt de diagnostiek van cutane lymfomen vaak lastig. 
Verschillende typen cutane lymfomen met een verschillend klinisch beloop en 
overlevingsverwachting kunnen eenzelfde histologisch beeld geven. Dit impliceert 
dat het voor een patholoog in veel gevallen onmogelijk is om alleen op basis van het 
histologisch beeld een defi nitieve diagnose te stellen. Combinatie van de klinische 
observatie en de histopathologie is essentieel om te komen tot een correcte 
diagnose. Het stellen van een goede diagnose is van belang om de patiënt de 
meest geschikte therapie te kunnen geven en te voorkomen dat onnodig agressief 
behandeld wordt. Een correcte diagnose maakt het ook mogelijk om relevante 
informatie en een reële prognose te kunnen geven aan de patiënt. Hoewel in 
de praktijk de meeste cutane lymfomen geclassifi ceerd kunnen worden volgens 
de classifi catie van de World Health Organization – European Organization for 
Research and Treatment of Cancer (WHO-EORTC), blijkt het in sommige gevallen 
zeer lastig om tot een defi nitieve diagnose te komen. Het is daarom van grote 
betekenis om te kunnen beschikken over aanvullende diagnostische biomarkers 
waarmee een duidelijk onderscheid kan worden gemaakt tussen de verschillende 
soorten cutane lymfomen. 
Het molecuul programmed death-1 (PD-1) heeft de afgelopen jaren veel aandacht 
gekregen van onderzoekers op het gebied van de tumorimmunologie. PD-1 vervult 
een belangrijke rol in de negatieve regulatie van de cellulaire immuunrespons. 
Opmerkelijk is dat de expressie van PD-1 een belangrijke biomarker blijkt te zijn 
voor het onderscheid tussen verschillende typen non-Hodgkin T-cellymfomen met 
extracutane lokalisaties. In de studies beschreven in dit proefschrift is onderzocht 











Het eerste deel van Hoofdstuk 1 geeft een gedetailleerd overzicht over het 
eiwit PD-1 dat centraal staat in dit proefschrift. Gestart wordt met een uitvoerige 
beschrijving van de kenmerken van het molecuul PD-1 en de liganden PD-L1 en 
PD-L2 die aan PD-1 kunnen binden. Ook wordt aangegeven welke cellen deze 
membraaneiwitten tot expressie brengen. Zo blijkt bijvoorbeeld dat conventionele 
T cellen pas na activatie PD-1 tot expressie brengen op de celmembraan, terwijl 
zogenaamde folliculaire helper T cellen dit eiwit constitutief tot expressie brengen. 
In detail wordt het mechanisme beschreven hoe de functie van geactiveerde 
conventionele T cellen geremd wordt na interactie van PD-1 met ligand PD-L1 of 
PD-L2. Als gevolg van deze interactie vermindert de proliferatie van de T cellen, 
neemt de cytokine productie (onder andere IL-2, IFN- en TNF-) af en wordt 
geprogrammeerde celdood (apoptosis) gestimuleerd. Geactiveerde T cellen, met 
name CD8-positieve cytotoxische T cellen, zijn essentieel voor het elimineren van 
tumorcellen. Als tumorcellen het ligand voor PD-1 tot expressie brengen zijn ze in 
staat om geactiveerde T cellen functioneel te remmen via interactie met PD-1, en op 
deze wijze zich te verweren tegen aanvallen van PD-1-positieve tumorinfi ltrerende 
T cellen die de tumor proberen te killen. Inmiddels is aangetoond dat blokkade van 
deze PD-1/PD-L1 interactie een veelbelovende behandeling is voor verschillende 
soorten kanker.
Het tweede deel van Hoofdstuk 1 beschrijft de expressie van PD-1 in nodale 
non-Hodgkin lymfomen en het belang van dit molecuul bij de diagnosis. Tenslotte 
worden de klinische en histopathologische kenmerken van verschillende typen 
primaire cutane lymfomen uitvoerig beschreven. De heterogene groep van cutane 
lymfomen kan onderverdeeld worden in twee hoofdgroepen: circa 75–80% 
wordt gevormd door cutane T-cellymfomen (CTCL) en 20–25% door cutane 
B-cellymfomen (CBCL). Beide groepen kunnen weer verder onderverdeeld worden 
in verschillende typen CTCL en CBCL. Het blijkt dat kennis over PD-1 expressie bij 
de verschillende typen cutane lymfomen gering of afwezig is.
In de in Hoofdstuk 2 beschreven studie is onderzocht of PD-1 een bruikbare 
diagnostische marker is waarmee verschillende typen CTCL van elkaar 
onderscheiden kunnen worden. Het is belangrijk dat het primair cutaan CD4+ 
klein/middelgrootcellig pleomorf T-cellymfoom (PCSM-TCL), dat een uitstekende 
prognose heeft, onderscheiden wordt van andere typen CTCL, in het bijzonder 
het primair cutaan perifeer T-cellymfoom, not otherwise specifi ed (PTCL–NOS) en 
tumorstadium mycosis fungoides (MF), omdat ze naast een compleet verschillende 
prognose ook sterk verschillen in geschikte behandelingsmethoden. Naast PD-1 
is ook de expressie van BCL6, CXCL13 en CD10 bepaald om een mogelijke relatie 
met folliculaire helper T cellen te bepalen, welke co-expressie van genoemde 
4 markers hebben. We vonden bij alle 26 patiënten met PCSM-TCL of met een 










CXCL13 tot expressie brachten, maar geen CD10. Expressie van PD-1 werd slechts 
bij 2 van de 21 patiënten met MF en bij 2 van de 16 patiënten met een PTCL–NOS 
gevonden. Samenvattend kan worden gesteld dat PD-1 expressie door atypische 
cellen kenmerkend is voor PCSM-TCL en cutane pseudo-T-cellymfoom en dat PD-1 
niet of nauwelijks tot expressie wordt gebracht bij andere typen CTCL. Deze studie 
toont aan dat PD-1 een bruikbare aanvullende marker is bij de diagnostiek van 
PCSM-TCL, en tevens dat de atypische T cellen in PCSM-TCL en cutane pseudo-
T-cellymfoom fenotypisch lijken op folliculaire helper T cellen. Verder ondersteunt 
onze studie de visie dat PCSM-TCL en cutane pseudo-T-cellymfomen, die zich met 
een solitaire laesie presenteren niet apart geclassifi ceerd moeten worden maar 
samen één entiteit vormen.
De studie beschreven in hoofdstuk 2 liet zien dat in slechts 2 van de 21 MF 
patiënten PD-1 expressie kon worden gedetecteerd in de huidbiopsieën op 
neoplastische cellen. Dit resultaat verschilt van gepubliceerde studies van andere 
onderzoeksgroepen, die rapporteerden dat PD-1 expressie gewoonlijk kan worden 
waargenomen in het merendeel van de MF patiënten en ook in patiënten met 
Sézary syndroom (SS). Sommigen beschouwen SS als een leukemische fase van MF 
vanwege overlap in een aantal kenmerken, maar hierover bestaat geen consensus. 
Naar aanleiding van de tegenstrijdige waarnemingen omtrent PD-1 expressie bij 
MF patiënten hebben we een studie uitgevoerd met een groot cohort MF patiënten 
en includeerden ook patiënten met erythrodermatisch MF en SS. Deze studie is 
beschreven in Hoofdstuk 3. We vonden dat PD-1 tot expressie werd gebracht door 
meer dan 50% van de neoplastische T cellen bij 8 van de 60 MF patiënten (13%). Bij 
erythrodermatisch MF werd PD-1 expressie in slechts 1 van de 8 patiënten (12%) 
aangetoond. In tegenstelling tot de situatie bij (erythrodermatische) MF,vonden 
we een sterke PD-1 expressie door meer dan 50% van de neoplastische T cellen bij 
24 van de 27 SS patiënten (89%). Deze studie bevestigt onze eerdere bevindingen 
(hoofdstuk 2) dat PD-1 positiviteit slechts bij een laag percentage MF kan worden 
aangetoond. Een waarschijnlijke verklaring voor de tegengestelde waarnemingen 
van andere onderzoeksgroepen is dat zij een ander drempelwaarde voor PD-1 
positiviteit gehanteerd hebben. Volgens onze defi nitie was er pas sprake van 
positiviteit als meer dan 50% van de neoplastische T cellen PD-1 kleuring liet 
zien, terwijl andere onderzoeksgroepen hun samples al positief beschouwden 
als 25% van de neoplastische T cellen PD-1 positief waren. In sommige studies 
was de drempelwaarde niet gedefi nieerd. Onze studie toont aan dat MF en SS 
differentiële PD-1 expressie hebben en deze bevinding ondersteunt de visie dat 
MF en SS verschillende entiteiten zijn.
Het is bekend dat het histopathologisch onderscheid tussen SS en een 
erythrodermie op basis van een goedaardige aandoening extreem moeilijk kan 










SS patiënten, maar informatie over PD-1 expressie in goedaardige vormen van 
erythrodermie ontbrak. In de studie beschreven in Hoofdstuk 4 is de expressie 
van PD-1 onderzocht in huidbiopten van 30 patiënten met verschillende typen 
erythrodermatische dermatitis (12 gevallen met een idiopatische erythrodermie, 
10 met een atopische erythrodermie, 6 met een psoriatische erythrodermie en 
2 met een paraneoplastische erythrodermie) en vergeleken met de expressie in 
huidbiopsieën van 25 SS patiënten uit een eerdere studie. We vonden dat PD-1 
tot expressie werd gebracht door meer dan 50% van het T-cel infi ltraat bij 23 
van de 25 SS patiënten (92%), terwijl dit bij slechts 4 van de 30 patiënten met 
een erythrodermatische dermatitis het geval was (13%). Opvallend was dat PD-1 
expressie aanwezig was op CD4+ neoplastische T cellen bij SS, maar voornamelijk op 
dermale en epidermale CD8+ T cellen bij erythrodermatische dermatitis. Expressie 
van CD7 door ≤ 20% van het T-cel infi ltraat werd alleen gevonden in SS huidcoupes 
en in geen enkel preparaat van de 30 patiënten met een goedaardige vorm van 
erythrodermie. Onze studie toont aan dat PD-1 een bruikbare marker is bij de 
diagnostiek van een patient met een erythrodermie: indien in een huidbiopsie 
van een patiënt met een erythrodermie aangetoond wordt dat PD-1 tot expressie 
komt bij meer dan 50% van de CD4+ T cellen en/of CD7 bij ≤ 20% van het T-cel 
infi ltraat, dan is dit een sterke aanwijzing voor de diagnose SS.
In de studie in Hoofdstuk 5 maakten we gebruik van een deel van dezelfde 
patiëntcohorten die ook werden gebruikt in het voorafgaande hoofdstuk. Het 
doel van deze studie was om te onderzoeken of de markers thymocyte selection-
associated high mobility group box protein (TOX, een chromatine-geassocieerd 
eiwit) en transcriptiefactor C-MYC bruikbaar zijn als aanvullende diagnostische 
markers om SS te onderscheiden van goedaardige vormen van erythrodermie. 
Het was al bekend dat beide markers tot expressie komen in MF en SS, maar 
het was nog onbekend in hoeverre deze markers tot expressie komen bij een 
erythrodermatische dermatitis. We vonden dat TOX sterk in de kern tot expressie 
werd gebracht door meer dan 50% van de T cellen bij 13 van de 15 SS patiënten 
(87%), terwijl TOX zwak tot expressie werd gebracht bij minder dan 50% (mediaan 
25%) van het T-cel infi ltraat bij de erythrodermatische dermatitis patiënten. De 
cohorten SS en goedaardige erythroderma lieten geen verschil zien in C-MYC 
expressie. In beide groepen was de expressie C-MYC laag en varieerde tussen < 
10% en 25%. Onze studie toont aan dat TOX expressie door meer dan 50% van 
het T-cel infi ltraat een bruikbaar hulpmiddel is bij het onderscheid tussen SS en 
een goedaardige vorm van erythrodermie, terwijl C-MYC onbruikbaar is voor dit 
onderscheid.
Er zijn diverse publicaties over PD-1 expressie in nodale B-cel non-Hodgkin 
lymfomen. In het algemeen werd gevonden dat PD-1 niet aanwezig is op de 
neoplastische B cellen, maar wel (in wisselende hoeveelheden), op tumorinfi ltrerende 










verhoogde aantallen PD-1+ T cellen geassocieerd is met een betere overleving. 
Informatie over PD-1 expressie in de verschillende typen CBCL was nagenoeg 
afwezig. In de studie beschreven in Hoofdstuk 6 hebben we daarom de expressie 
en distributie van PD-1 op neoplastische B cellen en reactieve T cellen in primaire 
CBCL onderzocht: 10 patiënten met primair cutaan marginale zone lymfoom 
(PCMZL), 18 met primair cutaan follikelcentrumcellymfoom (PCFCL) en 12 met 
primair cutaan diffuus grootcellig B-cellymfoom , beentype (PCDLBCL–LT). We 
vonden dat neoplastische B cellen negatief waren voor PD-1 behalve 2 gevallen 
met PCDLBCL–LT. De frequentie PD-1+ T cellen in huidcoupes van PCFCL, PCMZL 
en PCDLBCL–LT patiënten was respectievelijk 20%, 10% en 3% van het totale aantal 
infi ltraatcellen en respectievelijk 60%, 20% en 15% van het totaal aantal infi ltraat 
T cellen. De frequentie PD-1+ T cellen in huidcoupes van PCFCL patiënten was 
signifi cant hoger dan in PCMZL en PCDLBCL–LT. Onze studie toont aan dat PD-1 
zelden tot expressie komt op neoplastische cellen in CBCL. Tevens suggereert onze 
studie dat aanwezigheid van hoge percentages PD-1+ T cellen, in het bijzonder 
wanneer deze gelokaliseerd zijn buiten het kiemcentrum, een ondersteuning is 
voor de diagnose PCFCL. We hebben geen aanwijzing gevonden dat het aantal 













AITL angioimmunoblastic T-cell lymphoma
ALCL anaplastic large cell lymphoma
BCL6 transcription factor B-cell lymphoma 6
C-ALCL cutaneous anaplastic large cell lymphoma
CBCL cutaneous B-cell lymphoma
CLL chronic lymphocytic leukemia
CTCL cutaneous T-cell lymphoma
CXCL13 chemokine C-X-C motif ligand 13
CXCR5 chemokine C-X-C motif receptor 5
EID erythrodermic infl ammatory dermatosis
E-MF erythrodermic mycosis fungoides
EORTC European Organization for Research and Treatment of Cancer
Ig immunoglobulin
IgC immunoglobulin constant region
IgV immunoglobulin variable region
IL interleukin
ITIM immunoreceptor tyrosine–based inhibitory motif




PCFCL primary cutaneous follicle center lymphoma
PCLBCL–LT primary cutaneous diffuse large B-cell lymphoma, leg type
PCSM-TCL primary cutaneous CD4+ small/medium-sized pleomorphic T-cell  
 lymphomas
PCMZL primary cutaneous marginal zone lymphoma
PD-1 programmed death-1
PD-L programmed death-1 ligand
PTCL–NOS peripheral T-cell lymphoma, not otherwise specifi ed
SS Sézary syndrome
TCR T-cell receptor
TFH follicular helper T cell
TOX thymocyte selection-associated high mobility group box protein
Treg regulatory T cell
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